悪性リンパ腫 臨床と病理 ―WHO分類(第4版)に基づいて―

出版社： 先端医学社
著者：
発行日： 2009-12-01
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784884075958
電子書籍版： 2009-12-01 （第1第1刷）
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

6,600 円(税込)

購入する

商品紹介

ＷＨＯ分類第4版―悪性リンパ腫診断・治療　最新の集大成―
悪性リンパ腫分類の国際標準WHO分類改訂第4版が2008年9月公表された。本書はその日本語版であるが、ただの病型分類の羅列にとどまらず、本分類が実臨床で果たす意義をわが国を代表するエキスパートが詳細に示した実践書である。【総論】ではＷＨＯ分類の概説と診断・治療の基本事項とトピックスを、【各論】の<病理><臨床>各項では、ＷＨＯ分類を理解し活かす治療法を解説。主な病型には<まとめ>の項が付され、見開きで基本事項が把握可能である。リンパ腫に付随する造詣を深められる<コラム>も随所に登場。血液専門医、病理医、それを目指して研修中の医師をはじめ悪性リンパ腫に接する機会のある各科の医療関係者必携の集大成。

目次

  • 表紙
  • B細胞腫瘍,T / NK細胞腫瘍,およびHodgkinリンパ腫のWHO分類（第4版）
  • 改定序
  • 初版序
  • 執筆者一覧
  • 目次
  • 総論
  • 1. WHO分類が目指すもの
  • 2. WHO分類（第4版）の概要とおもな改訂点
  • 3. 免疫表現型（免疫染色,FCM）
  • 3-(1) 単クローン性抗体とノーベル賞
  • 3-(2) ヒト白血球分化抗原 / ヒト細胞分化分子
  • 3-(3) Rituximab
  • 4. 染色体・遺伝子異常と検査結果の解釈
  • 5. 悪性リンパ腫の予後因子および予後予測
  • 5 nm23について
  • 6. 悪性リンパ腫の病型頻度
  • 6-(1) 芽球とリンパ球
  • 6-(2) リンパ腫分類と皮膚リンパ腫
  • 7. 診断と治療のトピックス
  • 1) リンパ腫に対する新薬開発
  • 2） 悪性リンパ腫におけるPET / CTの有用性
  • 7-2) Standardized uptake value
  • 3） 90Y-lbritumomab tiuxetan（Zevalin）
  • 各論
  • Part I◆B細胞腫瘍
  • 1-0. B細胞腫瘍アウトライン
  • 1-1. Bリンパ芽球性白血病 / リンパ腫 <臨床と病理>
  • I 1-1-(1) Bリンパ芽球性リンパ腫で用いられる用語
  • I 1-1-(2) Tリンパ芽球性リンパ腫およびBリンパ芽球性リンパ腫の病理と臨床病態
  • 2-0. 濾胞性リンパ腫 <まとめ>
  • 2-1. 濾胞性リンパ腫 解説 <病理>
  • 2-2. 濾胞性リンパ腫 解説 <臨床>
  • I 2-2-(1) t(14;18)(q32;q21)型濾胞性リンパ腫とt(3;14)(q27;q32)型濾胞性リンパ腫
  • I 2-2-(2) 濾胞性リンパ腫のrituximab維持療法に関する知見
  • I 2-2-(3) 濾胞性リンパ腫のgrade進展,組織学的進展と+der（18）t（14;18）
  • 2-3. 腸管原発濾胞性リンパ腫 <臨床と病理>
  • 3-0. マントル細胞リンパ腫 <まとめ>
  • 3-1. マントル細胞リンパ腫 解説 <病理>
  • I 3-1-(1) マントル細胞リンパ腫の歴史
  • I 3-1-(2) CD5分子からみたリンパ腫
  • 3-2. マントル細胞リンパ腫 解説 <臨床>
  • I 3-2 マントル細胞リンパ腫と中枢神経系浸潤
  • 4-0. 節性濾胞辺縁帯リンパ腫 <まとめ>
  • 4-1. 節性濾胞辺縁帯リンパ腫 解説 <病理>
  • I 4-1-(1) リンパ腫と対応する正常細胞
  • I 4-1-(2) 濾胞辺縁帯リンパ腫の対応する正常細胞
  • 4-2. 節性濾胞辺縁帯リンパ腫 解説 <臨床>
  • I 4-2-(1) 小児節性濾胞辺縁帯リンパ腫
  • I 4-2-(2) 脾濾胞辺縁帯リンパ腫の治療
  • 4-3. 脾濾胞辺縁帯リンパ腫 <臨床と病理>
  • I 4-3-(1) 脾の系統発生
  • I 4-3-(2) 脾のリンパ腫分類
  • 5-0. びまん性大細胞型B細胞リンパ腫,非特異群 <まとめ>
  • 5-1. びまん性大細胞型B細胞リンパ腫,非特異群 解説 <病理>
  • 5-2. びまん性大細胞型B細胞リンパ腫,非特異群 解説 <臨床>
  • 5-3. 中・高齢者にみられるEBV陽性びまん性大細胞型B細胞リンパ腫（加齢性EBV関連B細胞リンパ増殖性疾患） <臨床と病理>A62
  • 5-4. 血管内大細胞型B細胞リンパ腫 <臨床と病理>
  • 5-5. 縦隔（胸腺）原発大細胞型B細胞リンパ腫 <臨床と病理>
  • I 5-5 縦隔(胸腺)原発大細胞型B細胞リンパ腫の治療戦略
  • 5-6. 中枢神経系原発びまん性大細胞型B細胞リンパ腫 <臨床と病理>
  • I 5-6-(1) 悪性リンパ腫の二次性中枢神経浸潤
  • I 5-6-(2) 中枢神経系原発びまん性大細胞型B細胞リンパ腫の治療方針
  • I 5-6-(3) 治療関連神経毒性
  • 5-7. ALK陽性大細胞型B細胞リンパ腫 <臨床と病理>
  • I 5-7 Anapiastic lymphoma kinase陽性大細胞型B細胞リンパ腫の鑑別のポイント
  • 5-8. 慢性炎症を伴ったびまん性大細胞型B細胞リンパ腫 <臨床と病理>
  • 5-9. CD5陽性びまん性大細胞型B細胞リンパ腫 <臨床と病理>
  • I 5-9 CD5陽性びまん性大細胞型B細胞リンパ腫に特徴的な病態
  • 5-10. その他のびまん性大細胞型B細胞リンパ腫 <臨床と病理>
  • I 5-10-(1) びまん性大細胞型B細胞リンパ腫の細分類
  • I 5-10-(2) びまん性大細胞型B細胞リンパ腫とEBウイルス
  • I 5-10-(3) びまん性大細胞型B細胞リンパ腫亜型分類と核小体
  • 6-0. Burkittリンパ腫 <まとめ>
  • 6-1. Burkittリンパ腫 解説 <病理>
  • I 6-1 Fluorescence in situ hybridization（FISH）法でC-MYC遺伝子異常を検索するには
  • 6-2. Burkittリンパ腫 解説 <臨床>
  • I 6-2 びまん性大細胞型B細胞リンパ腫とBurkittリンパ腫との中間型の特徴をもつ分類不能B細胞リンパ腫
  • 7-0-1. 節外性B細胞リンパ腫アウトライン
  • I 7-0-1-(1) 原発性浸出液リンパ腫
  • I 7-0-1-(2) 節外性濾胞辺縁帯B細胞リンパ腫の染色体異常
  • 7-0-2. 節外性濾胞辺縁帯リンパ腫：粘膜関連リンパ組織（MALT）リンパ腫 解説 <病理>
  • I 7-0-2-(1) 濾胞辺縁帯リンパ腫とリンパ腫分類
  • I 7-0-2-(2) 節外性濾胞辺縁帯リンパ腫における染色体・遺伝子異常の解釈
  • 7-1. 消化管B細胞リンパ腫 <臨床と病理>
  • I 7-1-(1) Helicobacter pyloriの診断法
  • I 7-1-(2) 病期I期胃MALTリンパ腫の治療戦略
  • I 7-1-(3) Multiple lymphomatoid polyposisを呈するマントル細胞リンパ腫の病理組織像
  • 7-2. 甲状腺リンパ腫 <臨床と病理>
  • I 7-2 甲状腺びまん性大細胞型B細胞リンパ腫に対する手術および放射線療法
  • 7-3. 眼付属器リンパ腫 <臨床と病理>
  • I 7-3-(1) 眼付属器とは
  • I 7-3-(2) 放射線晩期障害
  • I 7-3-(3) 眼付属器IgG4関連疾患
  • 7-4. 乳腺リンパ腫 <臨床と病理>
  • 7-5. 精巣リンパ腫 <臨床と病理>
  • 7-6. 骨リンパ腫 <臨床と病理>
  • 7-7. 肺リンパ腫 <臨床と病理>
  • 7-8. 子宮・卵巣リンパ腫 <臨床と病理>
  • 7-9. 鼻腔・副鼻腔リンパ腫 <臨床と病理>
  • 8. 高齢者リンパ腫の治療 <臨床と病理>
  • Part II◆TおよびNK細胞腫瘍
  • 1-0. TおよびNK細胞腫瘍アウトライン
  • II 1-0 T / NK細胞か? NK / T細胞か?
  • 1-1. Tリンパ芽球性白血病 / リンパ腫 <臨床と病理>
  • II 1-1-(1) Tリンパ芽球性リンパ腫におけるcytarabine大量療法と中枢神経系浸潤予防
  • II 1-1-(2) 臨床医はリンパ腫を診断することはできないか?細胞表面形質と臨床病態から臨床医が推測する病理組織型
  • 2-0. 未分化大細胞型リンパ腫 <まとめ>
  • 2-1. 未分化大細胞型リンパ腫 解説 <病理>
  • 2-2. 未分化大細胞型リンパ腫 解説 <臨床>
  • II 2-2 皮膚原発未分化大細胞型リンパ腫
  • 3-0. 血管免疫芽球性T細胞リンパ腫 <まとめ>
  • 3-1. 血管免疫芽球性T細胞リンパ腫 解説 <病理>
  • 3-2. 血管免疫芽球性T細胞リンパ腫 解説 <臨床>
  • II 3-2-(1) 血管免疫芽球性T細胞リンパ腫の“歴史”
  • II 3-2-(2) 細胞表面nm23について
  • 4-0. 末梢性T細胞リンパ腫,非特異群 <まとめ>
  • 4-1. 末梢性T細胞リンパ腫,非特異群 解説 <病理>
  • 4-2. 末梢性T細胞リンパ腫,非特異群 解説 <臨床>
  • II 4-2-(1) 末梢性T細胞リンパ腫に対する新薬
  • II 4-2-(2) 高齢者再発あるいは難治性末梢性T細胞リンパ腫に対するCMD療法
  • 5-0. 節外性NK / T細胞リンパ腫,鼻型 <まとめ>
  • 5-1. 節外性NK / T細胞リンパ腫,鼻型 解説 <病理>
  • 5-2. 節外性NK / T細胞リンパ腫,鼻型 解説 <臨床>
  • 6-0. 成人T細胞白血病 / リンパ腫 <まとめ>
  • 6-1. 成人T細胞白血病 / リンパ腫 解説 <病理>
  • 6-2. 成人T細胞白血病 / リンパ腫 解説 <臨床>
  • 7-1. その他の末梢性T細胞リンパ腫 <臨床と病理>
  • Part III◆Hodgkinリンパ腫
  • 1-0. Hodgkinリンパ腫 <まとめ>
  • 1-1. Hodgkinリンパ腫 解説 <病理>
  • III 1-1 びまん性大細胞型B細胞リンパ腫と古典的Hodgkinリンパ腫との中間型の特徴をもつ分類不能B細胞リンパ腫
  • 1-2. Hodgkinリンパ腫 解説 <臨床>
  • III 1-2 Hodgkinリンパ腫治療後の長期にわたる致命的な心筋梗塞のリスク
  • Part IV◆免疫不全症関連リンパ増殖性疾患
  • 1-1. 免疫不全症関連リンパ増殖性疾患-MTX関連を中心に- <臨床と病理>
  • 1-2. 免疫不全症関連リンパ増殖性疾患-MTX関連以外- <臨床と病理>
  • IV 1-2 悪性リンパ腫診断と抗HIV抗体測定
  • 索引
  • 奥付

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

総論

P.9 掲載の参考文献
1) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008
 
2) Jaffe ES, Harris NL, Stein H, et al.:World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2001
 
3) Harris NL, Jaffe ES, Stein H, et al.:A revised European-American classification of lymphoid neoplasms:a proposal from the international lymphoma study group. Blood 84:1361-1392, 1994
 
4) Willemze R, Kerl H, Sterry W, et al.:EORTC classification for primary cutaneous lymphomas:a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354-371, 1997
 
5) Willemze R, Jaffe ES, Burg G, et al.:WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005
PubMed
6) Oyama T, Ichimura, K, Suzuki R, et al.:Senile EBV+ B-cell lymphoproliferative disorders:a clinicopathologic study of 22 patients. Am J Surg Pathol 27:16-26, 2003
PubMed
7) Shimoyama Y, Yamamoto K, Asano N, et al.:Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders:special references to lymphomas surrounding this newly recognized clinicopathologic disease. Cancer Sci 99:1085-1091, 2008
PubMed
8) Kimura H, Morishima T, Kanegane H, et al.:Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 187:527-533, 2003
PubMed
9) Ohshima K, Kimura H, Yoshino T, et al.:Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults:overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int 58:209-217, 2008
 
10) Savage KJ, Harris NL, Vose JM, et al.:ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified:report from the International Peripheral T-Cell Lymphoma Project. Blood 111:5496-5504, 2008
 
P.20 掲載の参考文献
1) Gorczyca W, Emmons F:Atlas of Differential Diagnosis in Neoplastic, Hematopathology, 2nd ed, Informa Healthcare, UK, 2008
 
2) Kroft SH:Monoclones, monotypes, and neoplasia pittfalls in lymphoma diagnosis. Am J Clin Pathol 121:457-459, 2004
 
3) Rassenti LZ, Huynh L, Toy TL, et al.:ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351:893-901, 2004
PubMed
4) Wang X, Campoli M, Cho HS, et al.:A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Methods 299:139-151, 2005
PubMed
5) Rossi S, Laurino L, Furlanetto A, et al.:Rabbit monoclonal antibodies:a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Clin Pathol 124:295-230, 2005
PubMed
6) Herzenberg LA, Sweet RG, Herzenberg LA:Fluorescence-activated cell sorting. Sci Am 234:108-117, 1976
PubMed
7) Jennings CD, Foon KA:Recent advances in flow cytometry:application to the diagnosis of hematologic malignancy. Blood 90:2863-2892, 1997
 
8) Craig FE, Foon KA:Flow cytometric immunophenotyping for hematologic neoplasms. Blood 111:3941-3967, 2008
PubMed
9) Wilson WH:International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia. Cytometry B Clin Cytom 72(suppl 1):S2, 2007
 
10) Wood B:9-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med 130:680-690, 2006
PubMed
11) Hsi ED, Yegappan S:Lymphoma immunophenotyping:a new era in paraffin-section immunohistochemistry. Adv Anat Pathol 8:218-239, 2001
PubMed
12) Higgins RA, Blankenship JE, Kinney MC:Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. Arch Pathol Lab Med 132:441-461, 2008
PubMed
13) 武田麻衣子, 笠井孝彦, 榎本泰典ほか:自動免疫染色装置による免疫グロブリンL鎖 (IgL) mRNA検出. 第97回日本病理学会総会, 2008年5月15日, 金沢市
 
14) Kaleem Z:Flow cytometric analysis of lymphomas:current status and usefulness. Arch Pathol Lab Med 130:1850-1858, 2006
PubMed
15) 中峯寛和:悪性リンパ腫の病理診断学. 奈良医学雑誌 59:135-148, 2008
 
16) Nakase K, Kita K, Shiku H, et al.:Myeloid antigen, CD13, CD14, and/or CD33 expression is restricted to certain lymphoid neoplasms. Am J Clin Pathol 105:761-768, 1996
 
P.61 掲載の参考文献
・外村晶:染色体異常-ヒトの細胞遺伝学. 朝倉書店, 東京, 1978
 
・牧野佐二郎:染色体-人類の細胞遺伝. 医学書院, 東京, 1979
 
・Therman E:Human chromosomes, 2nd ed, Springer-Verlag, New York, 1980
 
・Shaffer LG, Tommerup N:ISCN (2005):An International System for Human Cytogenetic Nomenclature, ed by Shaffer LG, Slovak ML, Campbell LJ, Karger, Basel, 2005
 
・川島康平, 近藤誠 (訳):がん細胞遺伝学のガイドライン, 染色体核型記載の国際規約. An International System for Human Cytogenetic Nomenclature 1991 & 1985, 文光堂, 東京, 1994
 
・臨床染色体診断法, 古庄敏行, 吉田廸弘, 阿部達生ほか編, 古庄敏行監修, 金原出版, 東京, 1996
 
・阿部達生, 稲澤譲治:臨床FISHプロトコール, 秀潤社, 東京, 1997
 
・Barch MJ, Knutsen T, Spurback JL:The AGT cytogenetics laboratory manual, 3rd ed, Lippincott-Raven, USA, 1997
 
・阿部達生, 藤田弘子:新染色体異常アトラス, 南江堂, 東京, 1997
 
・阿部達生, 鎌田七男, 桜井雅温:腫瘍染色体アトラス, 南江堂, 東京, 1986
 
・阿部達生編著:造血器腫瘍アトラス-形態, 免疫, 染色体と遺伝子, 改訂第4版, 日本医事新報社, 東京, 2009
 
・佐藤祐子:血液疾患と染色体異常, 中外医学社, 東京, 1993
 
・横田昇平:分子生物学, 細胞遺伝学, 細胞免疫に基づく血液・固形腫瘍診断マニュアル改訂版, フジメディカル出版, 東京, 2002
 
・血液腫瘍-MIC-M 診断から治療まで-, 谷脇雅史編著, 先端医学社, 東京, 2005
 
・Sandberg AA:The chromosomes in human cancer and leukemia, 2nd ed, Elsevier, New York, 1990
 
・Heim S, Mitelman F:Cancer Cytogenetics, 2nd ed, Wiley-Liss, New York, 1995
 
・Atlas of Genetics and Cytogenetics in Oncology and Haematology (http://atlasgeneticsoncology.org//index.html)
 
・三浦偉久男:染色体検査の出し方と結果の解釈. 臨床血液 48:1393-1399, 2007
 
・三浦偉久男:造血器腫瘍における染色体転座. 臨床血液 49:318-324, 2008
 
・Miura I, Takahashi N, Kobayashi Y, et al.:Molecular cytogenetics of stem cells:Target cells of chromosomal aberrations as revealed by the application of fluorescence in situ hybridization to fluorescence-activated cell sorting. Int Hematol 72:310-317, 2000
 
・Abbas AK, Lichtman AH, Pillai S:Cellular and molecular immunology, 6th ed, Elsevier, Philadelphia, 2007
 
・Murphy K, Travers P, Walport M, et al.:Janeway's immunobiology, 7th ed, Garland Science, New York, 2008
 
・矢田純一:医系免疫学改訂10版, 中外医学社, 東京, 2007
 
・Brown TA:Genomes 3, Garland Science, New York, 2007
 
P.71 掲載の参考文献
1) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
PubMed
2) Noordijk EM, Carde P, Dupouy N, et al.:Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma:long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24:3128-3135, 2006
PubMed
3) Engert A, Schiller P, Josting A, et al.:Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma:results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3601-3608, 2003
 
4) Meyer RM, Gospodarowicz MK, Connors JM, et al.:Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma:National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:4634-4642, 2005
 
5) Hasenclever D, Diehl V:A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
 
6) Solal-Celigny P, Roy P, Colombat P, et al.:Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
PubMed
7) Buske C, Hoster E, Dreyling M, et al.:The Follicular lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate-or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108:1504-1508, 2006
PubMed
8) Dave SS, Wright G, Tan B, et al.:Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004
PubMed
9) Hoster E, Dreyling M, Klapper W, et al.:A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558-565, 2008
PubMed
10) Shah JJ, Fayad L, Romaguera J:Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. Blood 112:2583-2584, 2008
 
11) Gallamini A, Stelitano C, Calvi R, et al.:Peripheral T-cell lymphoma unspecified (PTCL-U):a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474-2479, 2004
 
12) Lee J, Suh C, Park YH, et al.:Extranodal natural killer T-cell lymphoma, nasal-type:a prognostic model from a retrospective multicenter study. J Clin Oncol 24:612-618, 2006
 
13) Vose J, Armitage J, Weisenburger D, et al.:International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008
PubMed
14) Alizadeh AA, Eisen MB, Davis RE, et al.:Distinct type of diffuse large B-cell lymphoma identified by gene expression profiling, Nature 403:503-511, 2000
PubMed
15) Rosenwald A, Wright G, Chan WC, et al.:The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
PubMed
16) Hans CP, Weisenburger DD, Greiner TC, et al.:Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 103:275-282, 2004
PubMed
17) Sehn LH, Berry B, Chhanabhai M, et al.:The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood 109:1857-1861, 2007
 
18) Nyman H, Adde M, Karjalainen-Lindsberg ML, et al.:Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109:4930-4935, 2007
PubMed
19) Fu K, Weisenburger DD, Choi WW, et al.:Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 26:4587-4594, 2008
PubMed
P.72 掲載の参考文献
i) Niitsu N, Okabe-Kado J, Kasukabe T, et al.:Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma. Blood 94:3541-3550, 1999
PubMed
ii) Niitsu N, Okabe-Kado J, Okamoto M, et al.:Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. Blood 97:1202-1210, 2001
 
iii) Niitsu N, Nakamine H, Okamoto M, et al.:Clinical significance of intracytoplasmic nm23-H1 expression in diffuse large B-cell lymphoma. Clin Cancer Res 10:2482-2490, 2004
PubMed
P.80 掲載の参考文献
1) The Non-Hodgkin's Lymphoma Pathologic Classification Project:National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas:Summary and description of a Working Formulation for clinical usage. Cancer 49:2112-2135, 1982
PubMed
2) Harris NL, Jaffe ES, Stein H, et al.:A revised European-American classification of lymphoid neoplasm:a proposal from the international lymphoma study group. Blood 84:1361-1392, 1994
 
3) World Health Organization Classification of Tumours. Pathology & Genetics of Tumours of Hematopoietic and Lymophoid Tissues, ed by Jaffe ES, Harris NL, Stein H, et al., IARC Press, Lyon, 2001
 
4) WHO Classification of Tumours of Haematopoietic and Lymophoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008
 
5) 岡本昌隆,新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO Classification分類第4版もふまえて-. 日本リンパ網内系雑誌49:86, 2009
 
6) Lymphoma Study Group of Japanese Pathologists:The World Health Organization classification of malignant lymphomas in Japan:Incidence of recently recognized entities. Pathol Int 50:696-702, 2000
 
7) The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group. Blood 89:3909-3918, 1997
 
8) Hans CP, Weisenberger DD, Greiner TC, et al.:Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004
 
P.81 掲載の参考文献
i) Ackerman AB, Nakano S:Acritique of classifications of lymphoma in historical perspective (and a proposal for how a classification that actually works can be formulated). Am J Dermatopathol 21:288-293, 1999
 
P.88 掲載の参考文献
1) Fisher RI, LeBlanc M, Press OW et al.:New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:8447-8452, 2005
PubMed
2) Feugier P, Van Hoof A, Sebban C, et al.:Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005
 
3) Watanabe T, Terui S, Itoh K, et al.:Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma. Cancer Sci 96:903-910, 2005
PubMed
4) Tobinai K, Watanabe T, Ogura M, et al.:Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 100:158-164, 2009
PubMed
5) Ogawa Y, Hotta T, Tobinai K, et al.:Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma. Ann Oncol 17:330-333, 2006
PubMed
6) Tobinai K, Watanabe T, Ogura M, et al.:Phase II study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin lymphoma. J Clin Oncol 24:174-180, 2006
PubMed
7) Stein R, Qu Z, Chen S, et al.:Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 10:2868-2878, 2004
PubMed
8) Morshhauser E Leonard JP, Coiffier B, et al.:Phase I/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL. Proc Am Soc Clin Oncol 24:7530 (abstr), 2006
 
9) Coiffier B, Lepretre S, Pedersen LM, et al.:Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia:a phase 1-2 study. Blood 111:1094-1100, 2008
PubMed
10) Hagenbeek A, Gadeberg O, Johnson P, et al.:First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma:results of a phase 1/2 trial. Blood 111:5486-5495, 2008
PubMed
11) Leonard Jp, Coleman M, Ketas JC, et al.:Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 21:3051-3059, 2003
PubMed
12) Leonard Jp, Coleman M, Katas JS, et al.:Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma:phase I/II clinical trial results. Clin Cancer Res 10:5327-5334, 2004
 
13) Leonard Jp, Coleman M, Ketas J, et al.:Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 23:5044-5051, 2005
PubMed
14) DiJoseph JE Armellino DC, Boghaert ER, et al.:Antibody-targeted chemotherapy with CMC-544:a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103:1807-1814, 2004
 
15) Tobinai K, Ogura M, Hatake K, et al.:Phase I and pharmacokinetic study of inotuzumab ozogamicin (CMC-544) as a single agent in Japanese patients with follicular lymphoma pretreated with rituximab. Blood (ASH Annual Meeting Abstracts), 112:1565, 2008
 
16) Gallamini A, Zaja E patti C, et al.:Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma:results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316-2323, 2007
 
17) Peleg AY, Husain S, Kwak EJ, et al.:Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody Clin Infect Dis 44:204-212, 2007
PubMed
18) Rodig SJ, Abramson JS, Pinkus GS, et al.:Heterogeneous CD-52 expression among hematologic neoplasms:implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 12:7174-7179, 2006
 
19) Rummel MJ, Al-Batran SE, Kim SZ, et al.:Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23:3383-3389, 2005
 
20) Carducci MA, Musib L, Kies MS, et al.:phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24:4092-4099, 2006
 
21) Robertson MJ, Kahl BS, Vose JM, et al.:Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 25:1741-1746, 2007
PubMed
22) Ishida T, Ueda R:CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 97:1139-1146, 2006
PubMed
23) Olsen EA, Kim YH, Kuzel TM, et al.:Phase II b multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25:3109-3115, 2007
PubMed
24) Balakrishnan K, Nimmanapalli R, Ravandi E et al.:Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood 108:2392-2398, 2006
 
25) O'Connor OA, Hamlin PA, Portlock C, et al.:Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 139:425-428, 2007
 
P.94 掲載の参考文献
1) Seam P, Juweid, Cheson BD, et al.:The role of FDG-PET scans in patients with lymphoma. Blood 110:3507-3516, 2007
PubMed
2) Schoder H, Noy A, Gonen M, et al.:Intensity of 18 fluorode-oxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 23:4643-4651, 2005
 
3) Cheson BD, Pfistner B, Juweid ME, et al.:Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
PubMed
4) Elstrom R, Guan L, Baker G, et al.:Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101:3875-3876, 2003
PubMed
5) Kako S, Izutsu K, Ota Y, et al.:FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 18:1685-1690, 2007
 
6) Bangerter M, Moog E Buchmann I, et al.:Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 9:1117-1122, 1998
 
7) Juweid ME, Wiseman GA, Vbse JM, et al.:Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23:4652-4661, 2005
 
8) Juweid ME, Stroobants S, Hoekstra OS, et al.:Use of positron emission tomography for response assessment of lymphoma:consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571-578, 2007
 
9) Kobe C, Dietlein M, Franklin J, et al.:Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112:3989-3994, 2008
PubMed
10) Gallamini A, Hutchings M, Rigacci L, et al.:Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma:a report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007
PubMed
11) Haioun C, Itti E, Rahmouni A, et al.:[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma:an early prognostic tool for predicting patient outcome. Blood 106:1376-1381, 2005
PubMed
12) Lin C, Itti E, Haioun C, et al.:Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma:SUV-based assessment versus visual analysis. J Nucl Med 48:1626-1632, 2007
PubMed
13) Zinzani PL, Stefoni V, Tani M, et al.:Role of [18F] Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma. J Clin Oncol 27:1781-1787, 2009
PubMed
14) Jerusalem G, Beguin Y, Fassotte ME et al.:Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 14:123-130, 2003
PubMed
P.101 掲載の参考文献
1) Chinn PC, Leonard JE, Rosenberg J, et al.:Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 15:1017-1025, 1999
PubMed
2) Press OW:Physics for practitioners:the use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphoma. Semin Hematol 37 (4 suppl 7):2-8, 2000
 
3) Wiseman GA, Leigh B, Erwin WD, et al.:Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 94(4 suppl):1349-1357, 2002
 
4) Witzig TE, White CA, Wiseman GA, et al.:Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20 (+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999
 
5) Gordon LI, Molina A, Witzig T, et al.:Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+B-cell lymphoma:long-term follow-up of a phase 1/2 study. Blood 103:4429-4431, 2004
PubMed
6) Witzig TE, Gordon LI, Cabanillas F et al.:Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002
 
7) Wiseman GA, Gordon LI, Multani PS, et al.:Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocy-topenia:a phase II multicenter trial. Blood 99:4336-4342, 2002
 
8) Witzig TE, Flinn IW, Gordon LI, et al.:Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-3269, 2002
PubMed
9) Schilder RJ, Emmanouilides C, Vb K, et al.:Yttrium 90 ibritumomab tiuxetan (Zebarin(R)) is safe and effective in older patients with relapsed or refractory NHL. Proc ASCO 23:(abstract 6562), 2005
 
10) Witzig TE, White CA, Gordon LI, et al.:Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21:1263-1270, 2003
 
11) Bennett JM, Kaminski MS, Leonard JB et al.:Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine 1131 tositumomab. Blood 105:4576-4582, 2005
 
12) Watanabe T Terui S, Itoh K, et al.:Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90) Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma. Cancer Sci 96:903-910, 2005
PubMed
13) Tobinai K, Watanabe T, Ogura M, et al.:Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 100:158-164, 2009
PubMed
14) Zinzani PL, d'Amore E Bombardieri E, et al.:Consensus conference:implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice-report of a European workshop. Eur J Cancer 44:366-373, 2008
 
15) Morschhauser E Radford J, Van Hoof A, et al.:Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-5164, 2008
 
16) Zinzani PL, Tani M, Fanti S, et al.:A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer 112:856-862, 2008
PubMed

各論

P.108 掲載の参考文献
1) Tonegawa S, Steinberg C, Dube S et al.:Evidence for somatic generation of antibody diversity Proc Natl Acad Sci USA 71:4027-4031, 1974
PubMed
2) Batista FD, Harwood NE:The who, how and where of antigen presentation to B cells. Nat Rev Immunol 9:15-27, 2009
 
3) Nakamura N, Abe M:Histogenesis of CD5-positive and CD5-negative B-cell neoplasms on the aspect of somatic mutation of immunoglobulin heavy chain gene variable region. Fukushima J Med Sci 49:55-67, 2003
PubMed
4) Broyde A, Boycov O, Strenov Y, et al.:Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol 84:338-343, 2009
PubMed
5) Kuppers R, Dalla-Favera R:Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20:5580-5594, 2001
 
6) Nakamura N, Abe M:Richter syndrome in B-cell chronic lymphocytic leukemia. Pathol Int 53:195-203, 2003
 
P.112 掲載の参考文献
1) Liu L, McGavran L, Lovell MA, et al.:Nonpositive terminal deoxynucleotidyl transferase in pediatric precursor B-lymphoblastic leukemia. Am J Clin Pathol 121:810-815, 2004
PubMed
2) Harewood L, Robinson H, Harris R, et al.:Amplification of AMLI on a duplicated chromosome 21 in acute lymphoblastic leukemia:a study of 20 cases. Leukemia 17:547-553, 2003
 
3) Hashimoto M, Yamashita Y, Mori N:Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias. J Pathol 197:341-347, 2002
PubMed
4) Cobaleda C, Busslinger M:Developmental plasticity of lymphocytes. Curr Opin Immunol 20:139-148, 2008
PubMed
5) Meyer C, Kowarz E, Hofmann J, et al.:New insights to the MLL recombinome of acute leukemias. Leukemia 23:1490-1499, 2009
 
6) Pui CH, Crist WM, Look AT:Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 76:1449-1463, 1990
PubMed
7) Harrison CJ:The detection and significance of chromosomal abnormalities in childhood acute lymphoblastic leukaemia. Blood Rev 15:49-59, 2001
PubMed
8) Yeoh EJ, Ross ME, Shurtleff SA, et al.:Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133-143, 2002
PubMed
9) Grimaldi JC, Meeker TC:The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. Blood 73:2081-2085, 1989
 
10) LeBrun DP:E2A basic helix-loop-helix transcription factors in human leukemia. Front Biosci 8:s206-s222, 2003
PubMed
11) Meijerink JP, den Boer ML, Pieters R:New genetic abnormalities and treatment response in acute lymphoblastic leukemia. Semin Hematol 46:16-23, 2009
PubMed
P.113 掲載の参考文献
i) 岡本昌隆:2. 活動状況・各種統計. 悪性リンパ腫・臨床と病理-ALTSG の研究から-, 平野正美編, 先端医学社, 東京, 2005, pp14-28
 
ii) 神野正敏:4. リンパ芽球白血病/リンパ腫. 悪性リンパ腫・臨床と病理-ALTSG の研究から-, 平野正美編, 先端医学社, 東京, 2005, pp146-150
 
P.122 掲載の参考文献
1) Ganti AK, Weisenburger DD, Smith LM, et al.:Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy:the Nebraska Lymphoma Study Group Experience. Ann Oncol 17:920-927, 2006
 
2) Martinez AE, Lin L, Dunphy CH:Grading of follicular lymphoma:comparison of routine histology with immunohistochemistry Arch Pathol Lab Med 131:1084-1088, 2007
PubMed
3) Wang SA, Wang L, Hochberg EP, et al:Low histologic grade follicular lymphoma with high proliferation index:morphologic and clinical features. Am Surg Pathol 29:1490-1496, 2005
PubMed
4) Karube K, Guo Y, Suzumiya J, et al.:CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood 109:3076-3079, 2007
PubMed
5) Agrawal R, Wang J:Pediatric follicular lymphoma:a rare clinicopathologic entity. Arch Pathol Lab Med 133:142-146, 2009
PubMed
6) Kojima M, Nakamura S, Ichimura K, et al.:Follicular lymphoma of the salivary gland:a clinicopathological and molecular study of six cases. Int J Surg Pathol 9:287-293, 2001
PubMed
7) Nakamura S, Ichimura K, Sato Y, et al.:Follicular lymphoma frequently originates in the salivary gland. Pathol Int 56:576-583, 2006
PubMed
8) Bacon CM, Ye H, Diss TC, et al.:Primary follicular lymphoma of the testis and epididymis in adults. Am J Surg Pathol 31:1050-1058, 2007
PubMed
9) Bacon CM, Diss TC, Ye H, et al.:Follicular lymphoma of the thyroid gland. Am J Surg Pathol 33:22-34, 2009
PubMed
10) Cong P, Raffeld M, Teruya-Feldstein J, et al.:In situ localization of follicular lymphoma:description and analysis by laser capture microdissection. Blood 99:3376-3382, 2002
PubMed
11) Willemze R, Jaffe ES, Burg G, et al:WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005
PubMed
12) Willemze R, Kerl H, Sterry W, et al.:EORTC classification for primary cutaneous lymphomas:a proposal from the cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354-371, 1997
 
13) Grange E Bekkenk MW, Wechsler J, et al.:Prognostic factors in primary cutaneous large B-cell lymphomas:a European multicenter study. J Clin Oncol 19:3602-3610, 2001
 
P.137 掲載の参考文献
1) 岡本昌隆, 新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO分類第4版もふまえて . 日本リンパ網内系雑誌 49:86, 2009
 
2) Freedman AS:Biology and Management of Histologic Transformation of Indolent Lymphoma. Hematology Am Soc Hematol Educ Program:314-320, 2005
PubMed
3) 中村栄男:A. 非ホジキンリンパ腫[1]B細胞a.普遍的な型3濾胞性リンパ腫. 新・悪性リンパ腫アトラス, 須知泰山, 菊池昌弘, 三方淳男ほか編, 文光堂, 東京, 2000, pp59-67
 
4) Yasukawa M, Bando S, Dolken G, et al.:Low frequency of BCL-2/JH translocation in peripheral blood lymphocytes of healthy Japanese individuals. Blood 99:486-488, 2001
 
5) Harris NL, Swerdlow SH, Jaffe ES, et al.:Follicular lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC, Lyon, 2008, pp220-226
 
6) Horning SJ:Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20 (suppl 5):75-88, 1993
 
7) Rosenberg SA:Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphoma:challenges and opportunities. J Clin Oncol 3:299-310, 1985
PubMed
8) Gine E, Montoto S, Bosch E et al.:The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological sub-type are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 17:1539-1545, 2006
 
9) Anderson JR, Vose JM, Bierman PJ, et al.:Clinical features and prognosis of follicular large-cell lymphoma:a report from the Nebraska Lymphoma Study Group. J Clin Oncol 11:218-224, 1993
 
10) Bartlett NL, Rizeq M, Dorinan RE et al.:Follicular large cell lymphoma:intermediate or low grade?J Clin Oncol 12:1349-1357, 1994
 
11) Weider RB, Jones D, Tucker SL, et al.:Long term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 51:1219-1227, 2001
 
12) Seymour JF pro B, Fuller LM, et al.:Long-term follow-up of a prospective study of combined modality therapy for stage I II indolent non-Hodgkin's lymphoma. J Clin Oncol 21:2115-2122, 2003
 
13) Horning SJ, Rosenberg SA:The natural history of initially untreated low-grade non-Hodgkin's lymphoma. N Engl J Med 311:1471-1475, 1984
PubMed
14) Young RC, Longo DL, Glatstein E, et al.:The treatment of indolent lymphomas:watchful waiting v aggressive combined modality treatment. Semin Hematol 25 (2 suppl 2):11-16, 1988
 
15) Salles GA:Clinical features, prognosis and treatment of follicular lymphoma. Hematology Am Soc Hematol Educ Program:216-225, 2007
PubMed
16) Dana BW, Dahlberg S, Nathwani BN, et al.:Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993
PubMed
17) Peterson BA, Petroni GR, Frizzera G, et al.:Prolonged single-agent versus combination chemotherapy in Indolent follicularlymphomas:a study of the cancer and leukemia group B. J Clin Oncol 21:5-15, 2003
 
18) Montoto S, Moreno C, Domingo-Domenech E, et al.:High clinical and molecular response rates with fuludarabine, cyclo-phosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Hematologica 93:207-214, 2008
 
19) Rummel MJ, Chow KU, Karakas T, et al.:Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle cell and low grade non Hodgkin's lymphoma. European J Cancer 38:1739-1746, 2002
 
20) Witzig TE, Vukov AM, Habermann TM, et al.:Rituximab therapy for patients with newly diagnosed, advanced-stage, follicu-lar grade 1 non-Hodgkin's lymphoma:A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23:1103-1108, 2005
 
21) Davis TA, Grillo-Lopwz AJ, White CA, et al.:Rituximab anti CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:Safety and efficacy of re-treatment. J Clin Oncol 18:3135-3143, 2000
 
22) Hiddemann W, Buske C, Dreyling M, et al.:Treatment strategies in follicular lymphomas:current status and future perspectives. J Clin Oncol 26:6394-6399, 2005
PubMed
23) Niitsu N, Hayama M, Okamoto M, et al.:Phase I study of rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma. Clin Cancer Res 10:4077-4082, 2004
PubMed
24) Witzig TE, Gordon LI, Cabanillas F et al.:Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radio-immunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-1463, 2002
 
25) Press OW, Unger JM, Braziel RM, et al.:Phase II trial of CHOP chemotherapy followed by tositumonab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma; Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24:4143-4149, 2006
 
26) Zinzani PL, Tani M, Pulsoni A, et al.:Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial:phase II non-randomised trial (FLUMIZ). Lancet Oncol 9:352-358, 2008
PubMed
27) Freedman AS, Neuberg D, mauch P, et al.:Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94;3325-3333, 1999
PubMed
28) Bierman PJ, Vose JM, Anderson JR, et al:High-dose therapy and autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15:445-450, 1997
PubMed
29) William CD, Godstone AH, Pearce RM, et al.:Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma:a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 14:2454-2464, 1996
 
30) Hunault-Berger m, Ifrah N, Solal-Celigny P, et al.:Intensive therapies in follicular non-Hodgkin lymphomas. Blood 100:1141-1152, 2002
PubMed
31) Schouten HC, Qian W, Kvaloy S, et al.:high-dose therapy improves progression-free surviaval and survival in relapsed follicular non-Hodgkin's lymphoma:results from the randomized European CUP trial. J Clin Oncol 21:3918-3927, 2003
 
32) Freedman As, Gribben JG Neuberg D, et al.:High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88:2780-2786, 1996
PubMed
33) van Besien K, Sobocinski KA, Rowlings PA., et al.:Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92:1832-1836, 1998
PubMed
34) van Besien K, Loberiza FR Jr, bajorunaite R, et al.:Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102:3521-3529,2003
PubMed
35) Robinson SP, Goldstone AH, Mackinnon S, et al.:Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation:an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100:4310-4316, 2002
PubMed
36) Solal-Celigny P, Roy P, Colombat P, et al.:Follicular lymphoma International Prognostic Index. Blood 104:1258-1265, 2004
PubMed
37) Tilly H, Rossi A, Stamatoullas A, et al.:Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 84:1043-1049, 1994
PubMed
38) Dave SS, Wright G, Tan B, et al.:Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004
PubMed
i) Tilly H, Rossi A, Stamatoullas A, et al.:Prognostic value of chronosomal abnormalities in follicular lymphoma. Blood 84;1043-1049, 1994
PubMed
P.143 掲載の参考文献
1) Yoshino T, Miyake K, Ichimura K, et al.:Increased incidence of follicular lymphoma in the duodenum. Am J Surg Pathol 24:688-693, 2000
PubMed
2) Sato Y, Ichimura K, Tanaka T, et al.:Duodenal follicular lymphoma share common characteristics with mucosa-associated lymphoid tissue lymphomas. J Clin Pathol 61:377-381, 2008
PubMed
3) Nakamura S, Ichimura K, Sato Y, et al.:Follicular lymphoma frequently originates in the salivary gland. Pathol Int 56:576-583, 2006
PubMed
4) Bacon CM, Diss TC, Ye H, et al.:Follicular lymphoma of the thyroid gland. Am J Surg Pathol 33:22-34, 2009
PubMed
5) Damaj G, Verkarre V Delmer A, et al.:Primary follicular lymphoma of the gastrointestinal tract:a study of 25 cases and a literature review. Ann Oncol 14:623-629, 2003
 
6) Takata K, Sato Y, Nakamura N, et al.:Duodenal and nodal follicular lymphomas are distinct:The former lacks activation-induced cytidine deaminase and follicular dendritic cells despite ongoing somatic hypermutations. Mod Pathol 22:940-949, 2009
PubMed
7) Aarts WM, Bende RJ, Steenbergen EJ, et al.:Variable heavy chain gene analysis of follicular lymphomas:correlation between heavy chain isotype expression and sornatic mutation load. Blood 95:2922-2929, 2000
 
8) Sato Y, Nakamura N, Nakamura S, et al.:Deviated VH4 immunoglobulin:gene usage is found among thyroid mucosa-associated lymphoid tissue lymphomas, similar to the usage at other sites, but is not found in thyroid diffuse large B-cell lymphomas. Mod Pathol 19:1578-1584, 2006
 
9) Bende RJ, Smit LA, Bossenbroek JG, et al.:Primary follicular lymphoma of the small intestine:α4β7 expression and immunoglobulin configuration suggest an origin from local antigen-experienced B-cells. Am J Pathol 162:105-113, 2003
 
10) Liu YX, Yoshino T, Ohara N, et al.:Loss of expression of α4β7integrin and L-selectin is associated with high-grade progression of low-grade MALT lymphoma. Mod Pathol 114:798-805, 2001
 
11) Toyoda H, Yamaguchi M, Nakamura S, et al.:Regression of primary lymphoma of the ampulla of Vater after eradication of Helicobacter pylori. Gastrointest Endosc 54:92-96, 2001
PubMed
P.152 掲載の参考文献
1) Swerdlow SH, Williams ME:From centrocytic to mantle cell lymphoma. a clinicopathologic and molecular review of 3 decades. Hum Pathol 33:7-20, 2002
PubMed
2) Swerdlow SH, Campo E, Seto M, et al.:Mantle cell lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp229-232
 
3) Tiemann M, Schrader C, Klapper W, et al.:Histopathology, cell proliferation indices, and clinical outcome in 304 patients with mantle cell lymphoma (MCL). a clinicopathologic study from the European MCL Network. Br J Haematol 131:29-38, 2005
PubMed
4) Norton AJ, Matthews J, Pappa V, et al.:Mantle cell lymphoma:natural history defined in a serially biopsied population over 20-year period. Ann Oncol 6:249-256, 1995
 
5) Swerdlow SH, Nathwani BN, Berger E et al.:Mantle cell lymphoma. In:WHO Classification of Tumours. Pathology and Genetics Tumours of Haematopoietic and Lymphoid Tissues, ed by Jaffe ES, Harris NL, Stein H, et al., IARC Press, Lyon, 2001, pp168-170
 
6) Liu Z, Dong HY, Gorczyca W, et al.:CD5-mantle cell lymphoma. Am J Clin Pathol 118:216-224, 2002
 
7) Schlette L, Fu K, Medeiros LJ:CD23 expression in mantle cell lymphoma:clinicopathologic features of 18 cases. Am J Clin Pathol 120:760-766, 2003
 
8) Dong HY, Gorczyca W, Liu Z, et al.:B-cell lymphomas with co-expression of CD5 and CD10. Am J Clin Pathol 119:218-230, 2003
 
9) Sriganeshan V, Blom TR, Weissmann DJ:A unique case of mantle cell lymphoma with an aberrant CD5-/CD10+immuno-phenotype and typical morphology. Arch Pathol Lab Med 132:1346-1349, 2008
 
10) Cheuk W, Wong KO, Wong CS, et al.:Consistent immunostaining for cyclin D1 can be achieved on a routine basis using a newly available rabbit monoclonal antibody Am J Surg Pathol 28:801-807, 2004
 
11) Determann O, Hoster E, Ott G, et al.:Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunotherapy:results from randomized trails of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 111:2385-2387, 2008
 
12) Romaguera JE, Medeiros LJ, Heagemeister FB, et al.:Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 97:586-591, 2003
 
13) Salar A, Juanpere N, Bellosillo B, et al.:Gastrointestinal involvement in mantle cell lymphoma. a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol 30:1274-1280, 2006
PubMed
P.164 掲載の参考文献
1) Weisenburger DD, Kim H, Rappaport H, et al.:Mantle-zone lymphoma:a follicular variant of intermediate lymphocytic lymphoma. Cancer 49:1429-1438, 1982
PubMed
2) Banks PM, Chan K, Cleary ML, et al.:Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 16:637-640,1992
 
3) Lymphoma Study Group of Japanese Pathologist:The World Health Organization Classification of malignant lymphomas in Japan:incidence of recently recognized entities. Pathol Int 50:696-702, 2000
 
4) 岡本昌隆, 新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO Classification分類第4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009
 
5) Hummel M, Tamaru J, Kalvelage B, et al.:Mantle cell (previously centrocytic) lymphomas express VH genes with no or very little somatic mutations like the physiologic cells of the follicle mantle. Blood 84:403-407, 1994
PubMed
6) Bosch F, Lopez-Guillermo A, Campo E, et al.:Mantle cell lymphoma:presenting features, response to therapy, and prognosotic factors. Cancer 82:567-575, 1998
PubMed
7) Weisenburger DD, Vose JM, Greiner TC, et al.; Mantle cell lymphoma. A clinicopathologic study of 68 cases from Nebraska Lymphoma Study Group. Am J Hematol 64:190-196, 2000
 
8) 二村聡, 松野吉宏:10. マントル細胞リンパ腫. 最新・悪性リンパ腫アトラス, 菊池昌広, 森茂郎編, 文光堂, 東京, 2004, pp154-161
 
9) Yatabe Y, Suzuki R, Robinai K, et al.:Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma:a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 95:2253-2261, 2000
 
10) Fisher RI, Dahlberg S, Nathwani BN, et al.:A Clinical analysis of two indolent lymphoma entities:mantle cell lymphoma and marginal zone lymphoma(including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories):85:1075-1082, 1995
PubMed
11) The Non-Hadgkin's Lymphoma Classification Project:A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997
 
12) Leithc HA, Gascoyne RD, Chhanabhai M, et al.:Limited-stage mantle-cell lymphoma. Ann Oncol 14:1555-1561, 2003
 
13) Meusers P, Engelhard M, Bartels H, et al.:Multicentre randomized therapeutic trial for advanced centrocytic lymphoma:Anthracycline dose not improve the prognosis. Hematol Oncol 7:365-380, 1989
 
14) Zucca E, Roggero E, Pinotti G, et al.:Patterns of survival in mantle cell lymphoma. Ann Oncol 6:257-262, 1995
PubMed
15) Ghielmini M, Schmitz SE Burki K, et al.:The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 11 (suppl 1):123-126, 2000
 
16) Foran JM, Rohatiner AZ, Cunningham D, et al.:European phase II study of Rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
 
17) Ghielmini, M, Schmitz SE Cogliatti S, et al.:Effect of single-agent rituximab given at the standard schedule or prolonged treatment in patients with mantle cell lymphoma:a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23:705-711, 2005
 
18) Howard OM, Gribben JG, Neuberg DS, et al.:Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma:molecular complete response are not predictivej of progression free survival. J Clin Oncol 20:1288-1294, 2002
 
19) Lenz G, Dreyling M, Hoster E, et al.:Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone signifanctly improves response and time to treatment failure, but not long-term outcome in patients to treatment failure, but not long term outcome in patients with previously untreated mantle cell lymphoma:Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23:1984-1992, 2005
 
20) Romaguera JE, Fayad L, Rodriguez MA, et al.:High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23:7013-7023, 2005
PubMed
21) Weigert O, Unterhalt M, Hiddemann W, et al.:Current management of mantle cell lymphoma. Drugs 67:1689-1702, 2007
PubMed
22) Forstpointner R, Dreyling M, Repp R, et al.:The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:results of a prospective randomized study of the German Low Grade Lymphoma Study Group. Blood 104:3064-3071, 2004
 
23) Forstpointner R, Unterhalt M, Dreyling M, et al.:Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas:results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood 108:4003-4008, 2006
 
24) Zhou Y, Zhang L, Romaguera J, et al.:Immunotherapy in mantle cell lymphoma:Anti-CD20-based therapy and beyond. Am J Hematol 83:144-149, 2008
PubMed
25) Freedman AS, Neuberg D, Gribben JG, et al.:High-dose Chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma:no evidence for long-term remission. J Clin Oncol 16:13-18, 1998
PubMed
26) Vose JM, Bierman PJ, Weisenburger DD, et al.:Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 6:640-645, 2000
PubMed
27) Decaudin D, Brousse N, Brice P, et al.:Efficacy of autologous stem cell transplantation in mantle cell lymphoma:a 3-year follow-up study. Bone Marrow Transplant 25:251-256, 2000
PubMed
28) Khouri IF, Romaguera J, Kantarjian H, et al.:Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation:an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803-3809, 1998
PubMed
29) Lefrere E Delmer A, Levy V, et al.:Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma:an update of prospective study. Haematologica 89:1275-1276, 2004
 
30) Dreyling M, Lenz G, Hoster E, et al.:Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma:results of a prospective randomized trial of the European MCL Network. Blood 105:2677-2684, 2005
PubMed
31) Gill S, Ritchie D:Therapeutic options in mantle cell lymphoma. Leuk Lymphoma 49:398-409, 2008
PubMed
32) Kasamon YL:Blood or marrow transplantation for mantle cell lymphoma. Curr Opin Oncol 19:128-135, 2007
 
33) Khouri IF Lee MS, Saliba RM, et al.:Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21:4407-4412, 2003
PubMed
34) Robinson SP, Goldstone AH, Mackinnon S, et al.:Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation:an analysis from Lyhmphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100:4310-4316, 2002
PubMed
35) Herold M, Schulze A, Niederwieser D, et al.:Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma:results of randomized phase III trial (OSHO#19). J Cancer Res Clin Oncol 132:105-112, 2006
 
36) Samaha H, Dumontet C, Ketterer N, et al.:Mantle cell lymphoma:a retrospective study of 121 cases. Leukemia 12:1281-1287, 1998
PubMed
37) Hoster E, Dreyling M, Klapper W, et al.:A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558-565, 2008
PubMed
38) Shah JJ, Fayad L, Romaguera J:Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. Blood 112:2583-2584, 2008
 
i) Oinonen R, Franssila K, Elonen E:Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol 78:145-149, 1999
PubMed
P.173 掲載の参考文献
1) Campo E, Pileri SA, Jaffe ES, et al.:Nodal marginal zone lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp218-219
 
2) Isaacson PG, Nathwani BN, Piris MA, et al.:Nodal marginal zone B-cell lymphoma. In:WHO Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, ed by Jaffe ES, Hards NL, Stein H, et al., IARC Press, Lyon, 2001, p161
 
3) Sheibani K, Sohn CC, Burke JS, et at.:Monocytoid B-cell lymphoma. A novel B-cell neoplasm. Am J Pathol 124:310-318, 1986
 
4) Cousar JB, McGinn DL, Glick AD, et al.:Report of an unusual lymphoma arising from parafollicular B lymphocytes (PBLs) or so-called "monocytoid" lymphocytes. Am J Clin Pathol 87:121-128, 1987
PubMed
5) Nizze H, Cogliatti SB, von Schilling C, et al.:Monocytoid B-cell lymphoma:morphological variants and relationship to low-grade B-cell lymphoma of the mucosa-associated lymphoid tissue. Histopathology 18:403-414, 1991
PubMed
6) Nathwani BN, Mohrmann RL, Brynes RK, et al.:Monocytoid B-cell lymphoma:an assessment of diagnostic criteria and a perspective on histogenesis. Hum Pathol 23:1061-1071, 1992
 
7) Davis GG, York JC, Glick AD, et al.:Plasmacytic differentiation in parafollicular (monocytoid) B-cell lymphoma. A study of 12 cases. Am J Surg Pathol 16:1066-1074, 1992
PubMed
8) Nathwani BN, Anderson JR, Armitage JO, et al.:Marginal zone B-cell lymphoma:A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 17:2486-2492, 1999
PubMed
9) Camacho FI, Algara P, Mollejo M, et al.:Nodal marginal zone lymphoma:A heterogeneous tumor. A comprehensive analysis of a series of 27 cases. Am J Surg Pathol 27:762-771, 2003
PubMed
10) Traverse-Glehen A, Felman P, Callet-Bauchu E, et al.:A clinicopathologic study of nodal marginal zone B-cell lymphoma. A report of 21 cases. Histopathology 48:162-173, 2006
PubMed
11) Kojima M, Inagaki H, Motoori T, et al.:Clinical implications of nodal marginal zone B-cell lymphoma among Japanese. A study of 65 cases. Cancer Sci 98:44-49, 2007
PubMed
12) Taddesse-Heath L, Pittaluga S, Sorbara L, et al.:Marginal zone B-cell lymphoma in children and young adults. Am J Surg Pathol 27:522-531, 2003
 
13) Attygalle AD, Liu H, Shirali S, et al.:A typical marginal zone hyperplasia of mucosa-associated lymphoid tissue:A reactive condition of childhood showing immunoglobulin lambda light-chain restriction. Blood 104:3343-3348, 2004
 
14) Campo E, Miquel R, Krenacs L, et al.:Primary nodal marginal zone lymphomas of splenic and MALT type. Am J Surg Pathol 23:59-68, 1999
PubMed
15) Kojima M, Nakamura S, Itoh H, et al.:Occurrence of monocytoid B-cells in reactive lymph node lesions. Pathol Res Pract 194:559-565, 1998
PubMed
16) Gupta D, Lim MS, Medeiros LJ, et al.:Small lymphocytic lymphoma with perifollicular, marginal zone, or interfollicular differentiation. Mod Pathol 13:1161-1166, 2000
PubMed
17) Osborne BM, Butler JJ, Mackay B:Sinusoidal large cell ("histiocytic") lymphoma. Cancer 46:2484-2491, 1980
PubMed
18) Lai R, Medeiros LJ, Dabbagh L, et al.:Sinusoidal CD30-positive large B-cell lymphoma:a morphologic mimic of anaplastic large cell lymphoma. Mod Pathol 13:223-228, 2000
 
P.178 掲載の参考文献
1) Mollejo M, Camacho FI, Algara P, et al.:Nodal and splenic marginal zone B cell lymphomas. Hematol Oncol 23:108-118, 2005
 
2) Arcaini L, Paulli M, Burcheri S, et al.:Primary nodal marginal zone B-cell lymphoma:clinical features and prognostic assessment of a rare disease. Br J Haematol 136:301-304, 2007
PubMed
3) Kojima M, Inagaki H, Motoori T, et al.:Clinical implications of nodal marginal zone B-cell lymphoma among Japanese:study of 65 cases. Cancer Sci 98:44-49, 2007
PubMed
4) Suarez F, Lortholary O, Hermine O, et al.:Infection-associated lymphomas derived from marginal zone B cells:a model of antigen-driven lymphoproliferation. Blood 107:3034-3044, 2006
 
5) Kahl B, Yang D:Marginal Zone Lymphomas:Management of Nodal, Splenic, and MALT NHL. Hematology Am Soc Hematol Educ Program:359-364, 2008
PubMed
6) Zucca E, Bertoni E Stathis A, et al.:Marginal zone lymphomas. Hematol Oncol Clin North Am 22:883-901, 2008
 
7) Ferreri AJ, Zucca E:Marginal-zone lymphoma. Crit Rev Oncol Hematol 63:245-256, 2007
PubMed
8) Aviles A, Delgado S, Huerta-Guzman J:Marginal zone B cell lymphoma of the parotid glands:results of a randomised trial comparing radiotherapy to combined therapy. Eur J Cancer B Oral Oncol 32B:420-422, 1996
PubMed
9) Koh LP, Lim LC, Thng CH:Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. Med Oncol 17:225-228, 2000
 
10) Berger F, Felman P, Thieblemont C, et al.:Non-MALT marginal zone B-cell lymphomas:a description of clinical presentation and outcome in 124 patients. Blood 95:1950-1956, 2000
 
11) Economopoulos T, Psyrri A, Fountzilas G, et al.:Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation:promising results in marginal zone lymphoma. Leuk Lymphoma 49:68-74, 2008
PubMed
12) Fisher RI, Dahlberg S, Nathwani BN, et al.:A clinical analysis of two indolent lymphoma entities:mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories):a South-west Oncology Group study. Blood 85:1075-1082, 1995
 
13) Nathwani BN, Anderson JR, Armitage JO, et al.:Marginal zone B-cell lymphoma:A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 17:2486-2492, 1999
PubMed
14) Thieblemont C, Coiffier B:Management of marginal zone lymphomas. Curr Treat Options Oncol 7:213-222, 2006
PubMed
15) Camacho FI, Algara P, Mollejo M, et al.:Nodal marginal zone lymphoma:a heterogeneous tumor:a comprehensive analysis of a series of 27 cases. Am J Surg Pathol 27:762-771, 2003
PubMed
16) Petit B, Chaury MP, Le Clorennec C, et al.:Indolent lymphoplasmacytic and marginal zone B-cell lymphomas:absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup. Haematologica 90:200-206, 2005
 
P.182 掲載の参考文献
1) Schmid C, Kirkham N, Diss T, et al.:Splenic marginal zone cell lymphoma. Am J Surg Pathol 16:455-466, 1992
PubMed
2) Thieblemont C, Felman P, Calle-Bauchu E, et al.:Splenic marginal-zone lymphoma:a distinct clinical and pathological entity. Lancet Oncol 4:95-103, 2003
 
3) Matutes E, Oscier D, Montalban CF, et al.:Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 22:487-495, 2008
 
4) Mele A, Pulsoni A, Bianco E, et al.:Hepatitis C virus and B-cell non-Hodgkin lymphomas:an Italian multicenter case control study. Blood 102:996-999, 2003
 
5) Gimeno E, Salido M, Sole F, et al.:CD5 negative and CD5 positive splenic marginal B-cell lymphomas have differential cytogenetic patterns. Leuk Res 29:981-982, 2005
PubMed
6) Arcaini L, Zibellini S, Passamonti f, et al.:Splenic marginal zone lymphoma:Clinical clustering of immunoglobin heavy chain repertoires. Blood Cells Mol Dis 42:286-291, 2009
PubMed
7) Camacho FI, Mollejo M, Mateo MS, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma:a description of a series of 12 cases. Am J Surg Pathol 25:1268-1276, 2001
 
P.190 掲載の参考文献
1) Alizadeh AA, Eisen MB, Davis RE, et al.:Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000
PubMed
2) Rosenwald A, Wright G, Chan WC, et al.:Lymphoma/Leukemia Molecular Profiling Project:The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
 
3) Lenz G, Wright G, Dave SS, et al.:Lymphoma/Leukemia Molecular Profiling Project:Stromal gene signatures in large B-cell lymphomas. N Engl J Med 359:2313-2323, 2008
 
4) Yamaguchi M, Seto M, Okamoto M, et al.:De novo CD5+diffuse large B-cell lymphoma:a clinicopathologic study of 109 patients. Blood 99:815-821, 2002
PubMed
5) Kobayashi T, Yamaguchi M, Kim S, et al.:Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5-diffuse large B-cell lymphomas Cancer Res 63:60-66, 2003
 
6) Tagawa H, Tsuzuki S, Suzuki R, et al.:Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma:camparison between CD5-positive and CD5-negative cases. Cancer Res 64:5948-5955, 2004
 
7) Yoshioka T, Miura I, Kume S, et al.:Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma:chromosome aberrations affecting 8p21 and 11q13 cnstitute major subgroups with different overall survival. Genes Chromosomes Cancer 42:149-157, 2005
 
8) Nakamura N, Nakamura S, Yamaguchi M, eta al.:CD5+ diffuse large B-cell lymphoma consists of germline cases and hypermutated cases in the immunoglobulin heavy chain gene variable region. Int J Hematol 81:58-61, 2005
 
9) Hyo R, Tomita N, Takeuchi K, et al.:The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematol Oncol, 2009 (in press)
 
10) Hans CP, Weisenburge DD, Greiner TC, et al.:Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004
 
11) Muris JJ, Meijer CJ, Vos W, et al.:Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 208:714-723, 2006
PubMed
12) Choi WW, Weisenburger DD, Greiner TC, et al.:A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15:5494-5502, 2009
PubMed
13) Houldsworth J, Mathew S, Rao PH, et al.:REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 87:25-29, 1996
PubMed
14) Lenz G, Davis RE, Ngo VN, et al.:Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319:1676-1979, 2008
PubMed
P.202 掲載の参考文献
1) Stein H, Warnke RA, Chan WC, et al.:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2008
 
2) 岡本昌隆, 新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO分類第4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009
 
3) Hunt KE, Reichard KK:Diffuse large B-cell lymphoma. Arch Pathol Lab Med 132:118-124, 2008
PubMed
4) Hans CP, Weisenburger DD, Greiner TC, et al.:Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004
PubMed
5) Niitsu N, Okamoto M, Nakamura N, et al.:Prognostic impact of chromosomal alteration of 3q27 on nodal B-cell lymphoma:Correlation with histology, immunophenotype, karyotype, and clinical outcome in 329 consecutive patients. Leuk Res 31:1191-1197, 2007
PubMed
6) Niitsu N, Okamoto M, Miura I, et al.:Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma. Cancer Sci, 2008 (in press)
 
7) Niitsu N, Okamoto M, Miura I, et al.:Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 23:777-783, 2009
 
8) Alizadeh AA, Eisen MB, Davis RE, et al.:Distinct type of diffuse large B-cell lymphoma identified by gene expression profiling, Nature 403:503-511, 2000
PubMed
9) Tagawa H, Suguro M, Tsuzuki S, et al.:Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 106:1770-1777, 2005
PubMed
10) Lossos IS, Czerwinski DK, Alizadeh AA, et al.:Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350:1828-1837, 2004
 
11) Rosenwald A, Wright G, Chan WC, et al.:The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
PubMed
12) Miller TP, Dahlberg S, Cassady JR, et al.:Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998
PubMed
13) Horning SJ, Weller E, Kim K, et at.:Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma:Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22:3032-3038, 2004
 
14) Bonnet C, Fillet G, Mounier N, et al.:CHOP alone compa red with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients:a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25:787-792, 2007
 
15) Reyes E Lepage E, Ganem G, et al.:ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352:1197-1205, 2005
 
16) Persky DO, Unger JM, Spier CM, et al.:Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma:Southwest Oncology Group study OO14. J Clin Oncol 26:2258-2263, 2008
 
17) Pfreundschuh M, Trumper L, Osterborg A, et al.:CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffus e large-B-cell lymphoma:a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
 
18) Fisher RI, Gaynor ER, Dahlberg S, et al.:Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
PubMed
19) Coiffier B, Lepage E, Briere J, et al.:CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engt J Med 346:235-242, 2002
 
20) Feugier P, Van Hoof A, Sebban C, et al.:Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005
 
21) Sehn LH, Donaldson J, Chhanabhai M, et al.:Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027-5033, 2005
PubMed
22) Pfreundschuh M, Schubert J, Ziepert M, et al.:Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116, 2008
PubMed
23) Pfreundschuh M, Trumper L, Kloess M, et al.:Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas:results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004
 
24) Pfreundschuh M, Trumper L, Kloess M, et al.:Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas:results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633, 2004
 
25) Brusamolino E, Maffioli M, Bonfichi M, et al.:Front-line therapy for nonlocalized diffuse large B-cell lymphoma:what has been demonstrated and what is yet to be established. Future Oncol 4:199-210, 2008
PubMed
26) Tilly H, Lepage E, Coiffier B, et al.:Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289, 2003
 
27) Niitsu N, Okamoto M, Aoki S, et al.:Multicenter phase II study of the CyclOBEAP (CHOP-like+etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. Ann Hematol 85:374-380, 2006
PubMed
28) Philip T, Guglielmi C, Hagenbeek A, et al.:Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
PubMed
29) Kewalramani T, Zelenetz AD, Nimer SD, et al.:Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103:3684-3688, 2004
PubMed
30) Haioun C, Lepage E, Gisselbrecht C, et al.:Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma:final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 18:3025-3030, 2000
 
31) Lenz G, Wright G, Dave SS, et al.:Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313-2323, 2008
 
P.205 掲載の参考文献
1) Nakamura S, Jaffe ES, Swerdlow SH:EBV positive diffuse large B-cell lymphoma of the elderly In:WHO Classification Classtfication of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, pp243-244, 2008
 
2) Oyama T, Ichimura K, Suzuki R, et al.:Senile EBV+B-cell lymphoproliferative disorders:a clinicopathologic study of 22 patients. Am J Surg Pathol 27:16-26, 2003
PubMed
3) Oyama T, Yamamoto K, Asano N, et al.:Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group:a study of 96 patients. Clin Cancer Res 13:5124-5132, 2007
 
4) Asano N, Yamamoto K, Tamaru J, et al.:Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders:comparison with EBV-positive classical Hodgkin lymphoma in elderly patients. Blood 113:2629-2636, 2009
PubMed
P.208 掲載の参考文献
1) Nakamura S, Ponzoni M, Campo E:Intravascular large B-cell lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp252-253
 
2) Asada N, Odawara J, Kimura S, et al.:Use of random skin biopsy for diagnosis of intravascular large B-cell lymphoma. Mayo Clin Proc 82:1525-1527, 2007
 
3) Murase T, Yamaguchi M, Suzuki R, et al.:Intravascular large B-cell lymphoma (IVLBCL):a clinicopathologic study of 96 cases with special reference to the immunophenotypic hetero-geneity of CD5. Blood 109:478-485, 2007
 
4) Murase T, Nakamura S, Kawauchi K, et al.:An Asian variant of intravascular large B-cell lymphoma:clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated ith haemophagocytic syndrome. Br J Haematol 111:826-834, 2000
 
5) Murase T, Nakamura S:An Asian variant of intravascular lymphomatosis:an updated review of malignant histiocytosis-like B-cell lymphoma. Leuk Lymphoma 33:459-473, 1999
 
6) Murase T, Nakamura S, Tashiro K, et al.:Malignant-histiocytosis-like B-cell lymphoma, a distinct pathologic variant of intravascular lymphomatosis:a report of five cases and review of the literature. Br J Haematol 99:656-664, 1997
 
7) Ponzoni M, Ferreri AJ, Campo E, et at.:Definition, diagnosis, and management of intravascular large B-cell lymphoma:Proposals and perspectives from an international consensus meeting. J Clin Oncol 25:3168-3173, 2007
 
8) Yamaguchi M, Nakamura N, Suzuki R, et al. De novo CD5+ diffuse large B-cell lymphoma:results of a detailed clinicopathological review in 120 patients. Haematologica 93:1195-1202, 2008
PubMed
9) Takahashi E, Kajimoto K, Fukatsu T et al.:Intravascular large T-cell lymphoma:a case report of CD30-positive and ALK-negative anaplastic type with cytotoxic molecule expression. Virchows Arch 447:1000-1006, 2005
 
10) Shimada K, Matsue K, Yamamoto K, et al.:Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 26:3189-3195, 2008
 
P.212 掲載の参考文献
1) Perrone T, Frizzera G, Rosai J:Mediastinal diffuse large-cell lymphoma with sclerosis. A clinicopathologic study of 60 cases. Am J Surg Pathol 10:176-191, 1986
PubMed
2) Moldenhauer G, Popov SW, Wotschke B, et al.:AID expression identifies interfollicular large B cells as putative precur-sors of mature B-cell malignancies. Blood 107:2470-2473, 2006
 
3) Lymphoma Study Group of Japanese Pathologist. The World Health Organization classification of malignant lymphoma in Japan:Incidence of recently recognized entities. Pathol Int 50:696-702, 2000
 
4) Paulli M, Strater J, Gianelli U, et al.:Mediastinal B-cell lymphoma:a study of its histomorphologic spectrum based on 109 cases. Hum Pathol 30:178-187, 1999
PubMed
5) Kanavaros B Gaulard P, Charlotte E et al.:Discordant expression of immunoglobulin and its associated molecule mb-1/ CD79a is frequently found in mediastinal large B cell lymphomas. Am J Pathol 146:735-741, 1995
 
6) Pileri SA, Gaidano G, Zinzani PL, et al.:Primary mediastinal B-cell lymphoma:high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB. 1, and PU. 1 in the absence of immunoglobulins. Am J Pathol 162:243-253, 2003
PubMed
7) Calaminici M, Piper K, Lee AM, et al.:CD23 expression in mediastinal large B-cell lymphomas. Histopathology 45:619-624, 2004
 
8) de Leval L, Ferry JA, Falini B, et al.:Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma:evidence for derivation from germinal center B cells? Am J Surg Pathol 25:1277-1282, 2001
 
9) Copie-Bergman C, Gaulard P, Maouche-Chretien L, et al.:The MAL gene is expressed in primary mediastinal large B-cell lymphoma. Blood 94:3567-3575, 1999
 
10) Rodig SJ, Savage KJ, LaCasce AS, et al.:Expression of TRAFI and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol 31:106-112, 2007
 
11) Leithauser E Bauerle M, Huynh MQ, et al.:Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma. Blood 98:2762-2770, 2001
 
12) Wessendorf S, Barth TE Viardot A, et al.:Further deline ation of chromosomal consensus regions in primary mediastinal B-cell lymphomas:an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia 21:2463-2469, 2007
 
13) Rosenwald A, Wright G, Leroy K, et al.:Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198:851-862, 2003
PubMed
14) Savage KJ, Monti S, Kutok JL, et al.:The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871-3879, 2003
 
15) Traverse-Glehen A, Pittaluga S, Gaulard P, et al.:Mediastinal gray zone lymphoma:the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 29:1411-1421, 2005
 
i) Lazzarino M, Orlandi E, Paulli M, et al.:Primary mediastinal B-cell lymphoma with sclerosis:an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol 11:2306-2313, 1993
PubMed
ii) De Sanctis V, Finolezzi E, Osti ME et al.:MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma. Int J Radiat Oncol Biol Phys 72:1154-1160, 2008
 
iii) Jacobson JO, Aisenberg AC, Lamarre L et al.:Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy Cancer 62:1893-1898, 1998
 
P.219 掲載の参考文献
1) Batchelor T, Loeffle JS:Primary CNS lymphoma. J Clin Oncol 24:1281-1288, 2006
 
2) Bhagavathi S, Wilson JD:Primary central nervous system lymphoma. Arch Pathol Lab Med 132:1830-1834, 2008
PubMed
3) Deckert M, Paulus W:Malignant Lymphomas. In:WHO Classification of Tumours of the Central Nervous System, ed by Louis DN, Ohgaki H, Wiestler OD, et al., IARC Press, Lyon, 2007, pp188-192
 
4) Abrey LE, Batchelor TT, Ferreri AJ, et al.:Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034-5043, 2005
PubMed
5) Camilleri-Broet S, Criniere E, Broet P, et al.:Auniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas:analysis of 83 cases. Blood 107:190-196, 2006
 
6) Ferreri AJ, Blay JY, Reni M, et al.:Prognostic scoring system for primary CNS lymphomas:the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266-272, 2003
 
7) Nelson DE Martz KL, Bonner H, et al.:non-Hodgkin's lymphoma of the brain:can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG):RTOG 8315. Int J Radiat Oncol Biol Phys 23:9-17, 1992
 
8) Shibamoto Y, Ogino H, Hasegawa M, et al.:Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys 62:809-813, 2005
PubMed
9) Abrey LE, Yahalom J, DeAngelis LM:Treatment for primary CNS lymphoma:the next step. J Clin Oncol 18:3144-3150, 2000
PubMed
10) DeAngelis LM, Iwamoto FM:An update on therapy of primary central nervous system lymphoma. Hematology Am Soc Hematol Educ Program:311-316, 2006
 
11) DeAngelis LM, Seiferheld W, Schold SC, et al.:Combination chemotherapy and radiotherapy for primary central nervous system lymphoma:Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20:4643-4648, 2002
 
12) Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et at.:High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma:European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21:4483-4488, 2003
 
13) Ferreri AJ, Reni M, Pasini E et al.:A multicenter study of treatment of primary CNS lymphoma. Neurology 58:1513-1520, 2002
 
14) Pels H, Schmidt-Wolf IG, Glasmacher A, et al.:Primary central nervous system lymphoma:results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy J Clin Oncol 21:4489-4495, 2003
PubMed
15) Abrey LE, Ben-Porat L, Panageas KS, et al.:Primary central nervous system lymphoma:the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711-5715, 2006
 
16) Omuro AM, DeAngelis LM, Yahalom J, et al.:Chemoradiotherapy for primary CNS lymphoma:an intent-to-treat analysis with complete follow-up. Neurology 64:69-74, 2005
PubMed
P.224 掲載の参考文献
1) Delsol G, Campo E, Gascoyne RD, et al.:Alk-positive large B-cell lymphoma. In:WHO Classification Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris LN, et al., IARC Press, Lyon, 2008
 
2) Delsol G, Lamant L, Mariame B, et al.:A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 89:1483-1490, 1997
 
3) Gascoyne RD, Lamant L, Martin-Subero JI, et al.:ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements:report of 6 cases. Blood 102:2568-2573, 2003
PubMed
4) De Paepe P, Baens M, van Krieken H, et al.:ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 102:2638-2641, 2003
 
5) Reichard KK, McKenna RW, Kroft SH:ALK-positive diffuse large B-cell lymphoma:report of four cases and review of the literature. Mod Pathol 20:310-319, 2007
PubMed
6) Lee HW, Kim K, Kim W, et al.:ALK-positive diffuse large B-cell lymphoma:report of three cases. Hematol Oncol 26:108-113, 2008
PubMed
7) Momose S, Tamaru J, Kishi H, et al.:Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion. Hum Pathol 40:75-82, 2009
PubMed
8) Beltran B, Castillo J, Salas R, et al.:ALK-positive diffuse large B-cell lymphoma:report of four cases and review of the literature. J Hematol Oncol 2:11, 2009
 
9) Wang WY, Ma ZG, Li GD, et al.:Diffuse large B-cell lymphoma with expression of anaplastic lymphoma kinase protein:clinicopathologic and immunohistochemical study of 5 cases. Zhonghua Bing Li Xue Za Zhi 35:529-534, 2006
PubMed
10) Chiarle R, Voena C, Ambrogio C, et al.:The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8:11-23, 2008
PubMed
11) Chiarle R, Simmons WJ, Cai H, et al.:Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11:623-629, 2005
PubMed
12) Chiarle R, Martinengo C, Mastini C, et al.:The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med 14:676-680, 2008
PubMed
P.227 掲載の参考文献
1) Iuchi K, Ichimiya A, Akashi A, et al.:non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax. Cancer 60:1771-1775, 1987
PubMed
2) Aozasa K:Pyothorax-associated lymphoma. J Clin Exp Hematop 46:5-10, 2006
PubMed
3) Narimatsu H, Ota Y, Kami M, et al.:Clinicopathological features of pyothorax-associated lymphoma; a retrospective survey involving 98 patients. Ann Oncol 18:22-128, 2007
PubMed
4) Petitjean B, Jardin F, Joly B, et al.:Pyothorax-associated lymphoma:a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B-and T-cell phenotype. Am J Surg Pathol 26:724-732, 2002
 
5) Hongyo T, Kurooka M, Taniguchi E, et al.:Frequent p53 mutations at dipyrimidine sites in patients with pyothorax-associated lymphoma. Cancer. Res 58:1105-1107, 1998
PubMed
6) Nishiu M, Tomita Y, Nakatsuka S, et al.:Distinct pattern of gene expression in pyothorax-associated lymphoma (PAL), a lymphoma developing in long-standing inflammation. Cancer Sci 95:828-834, 2004
 
7) Cheuk W, Chan AC, Chan JK, et al.:Metallic implant-associated lymphoma:a distinct subgroup of large B-cell lymphoma related to pyothorax-associated lymphoma? Am J Surg Pathol 29:832-836, 2005
 
P.233 掲載の参考文献
1) Matolcsy A, Chadurn A, Knowles DM:De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol 147:207-215, 1995
 
2) Yamaguchi M, Seto M, Okamoto M, et al.:De novo CD5+ diffuse large B-cell lymphoma:a clinicopathologic study of 109 patients. Blood 99:815-821, 2002
PubMed
3) Yamaguchi M, Nakamura N, Suzuki R, et al.:De novo CD5+ diffuse large B-cell lymphoma:Results of a detailed clinicopathological review in 120 patients. Haematologica 93:1195-1202, 2008
PubMed
4) Ennishi D, Takeuchi K, Yokoyama M, et al.:CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituxi-mab plus CHOP therapy. Ann Oncol 19:1921-1926, 2008
 
5) Ogawa S, Yamaguchi M, Oka K, et al.:CD21S antigen expression in tumor cells of diffuse large B-cell lymphoma is an independent prognostic factor indicating better oveall survival. Br J Hematol 125:180-186, 2004
 
6) Maeshima AM, Taniguchi H, Nomoto J, et al.:Secondary CD5+ diffuse large B-cell lymphoma not associated with transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter syndrome). Am J Clin Pathol 131:339-346, 2009
 
7) Katzenberger T, Lohr A, Schwarz S, et al.:Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+progenitor B cell. Blood 101:699-702, 2003
 
8) Ybshioka T, Miura I, Kume M, et al.:Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma:Chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival. Genes Chromosomes Cancer 42:149-157, 2005
 
9) Kobayashi T, Yamaguchi M, Kim S, et al.:Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5-diffuse large B-cell lymphomas. Cancer. Res 63:60-66, 2003
 
10) Suguro M, Tagawa H, Kagami Y, et al.:Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup:Development of a CD5 signature. Cancer Sci 97:868-874, 2006
PubMed
11) Yamaguchi M, Ohno T, Oka K, et al.:De novo CD5-positive diffuse large B-cell lymphoma:clinical characteristics and therapeutic outcome. Br J Haematol 105:1133-1139, 1999
PubMed
12) Linderoth J, Jerkeman M, Cavallin-Stahl E, et al.:Immunohistochemical Expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma:A Nordic Lymphoma Group Study Clin Cancer Res 9:722-728, 2003
 
13) Johnson NA, Boyle M, Bashashati A, et al.:Diffuse large B-cell lymphoma:reduced CD20 expression is associated with an inferior survival. Blood 113:3773-3780, 2009
PubMed
14) Murase T, Yamaguchi M, Suzuki R, et al.:Intravascular large B-cell lymphoma (IVLBCL):a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 1O9:478-485, 2007
 
P.242 掲載の参考文献
1) De Wolf-Peeters C, Delabie J, Campo E, et al.:T cell-/histiocyte-rich large B-cell lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp238-239
 
2) Ramsay AD, Smith WJ, Isaacson PG:T cell-rich B-cell lymphoma. Am J Surg Pathol 12:433-443, 1988
 
3) Delabie J, Vandenberghe E, Kennes C, et al.:Histiocyte-rich large B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype. Am J Surg Pathol 16:37-48, 1992
 
4) Franke S, Wlodarska I, Maes B, et al.:Comparative genomic hybridization pattern distinguishes T-cell/histiocyte-rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin's lymphoma. Am J Pathol 161:1861-1867, 2002
 
5) Monti S, Savage KJ, Kutok JL, et al.:Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105:1851-1861, 2005
PubMed
6) Meijer CJLM, Vergier B, Duncan LM, et al.:Primary cutaneous DLBCL, leg type. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, p242
 
7) Yamamoto Y, Nakamine H, Nakamura S:Recurrent primary cutaneous large B-cell lymphoma after a long-term remission. Pathol Int 56:645-647, 2006
 
8) Burg G, Jaffe ES, Willemze R, et al.:Cutaneous diffuse large B-cell lymphoma. In:WHO Classification of Tumours. Pathology and Genetics of Skin Tumours, ed by LeBoit PE, Burg G, Weedron D, et al., IARC Press, Lyon, 2006, pp198-199
 
9) Willemze R, Swerdlow SH, Harris NL, et al.:Primary cutaneous follicle centre lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp227-228
 
10) Pittaluga S, Wilson WH, Jaffe ES:Lymphomatoid granulomatosis. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp247-249
 
11) Wilson WH, Kingma DW Raffeld M, et al.:Association of lym-phomatoid granulomatosis with Epstein Barr virus infection of Blymphocytes and response to interferon-alpha 2b. Blood 87:4531-4537, 1996
 
12) Stein H, Harris NL, Campo E:Plasmablastic lymphoma. In:WHO Classification Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IA. RC Press, Lyon, 2008, pp256-257
 
13) Colomo L, Loong E Rives S, et al.:Diffuse large B-cell lym-phomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg. Pathol 28:736-747, 2004
 
14) Isaacson PG, Campo E, Harris NL:Large B-cell lymphomas arising in HHV8-associated multicentric Castleman disease. In:WHO Classification of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp258-259
 
15) Jarviluoma A, Koopal S, Rasanen S, et al.:KSHV viral cyclin binds to p27KIP in primary effusion lymphomas. Blood 104:3349-3354, 2004
 
16) Du MQ, Liu H, Diss TC, et al.:Kaposi sarcoma-assoc iated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoprolif-erative disorders. Blood 97:2130-2136, 2001
 
17) Chadburn A, Hyjek EM, Tam W, et al.:Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV;HHV-8)-infected B cells in HIV+multicentric Castleman disease (MCD). Histopathology 53:513-524, 2008
PubMed
18) Said J, Cesarman E:Primary effusion lymphoma. In:WHO Classification of Tumours Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp260-261
 
19) Hollingsworth HC, Stetler-Stevenson M, Gagneten D, et al.:Immunodeficiency-associated malignant lymphoma. Three cases showing genotypic evidence of both T-and B-cell lineages. Am J Surg Pathol 18:1092-1101, 1994
 
20) Klein U, Gloghini A, Gaidano G, et al.:Gene expression pro-file analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 101:4115-4121, 2003
 
i) WHO Classification of Tumours Of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008
 
P.250 掲載の参考文献
1) Magrath IT:African Burkitt's lymphoma. History, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol 13:222-246, 1991
PubMed
2) Hecht JL, Aster JC:Molecular biology of Burkitt's lymphoma. J Clin Oncol 18:3707-3721, 2000
PubMed
3) Hummel M, Bentink S, Berger H, et al.:Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419-2430, 2006
PubMed
4) Dave SS, Fu K, Wright GW et al.:Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 354:2431-2442, 2006
PubMed
5) Nakamura N, Nakamine H, Tamaru J, et al.:The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement. Mod Pathol 15:771-776, 2002
 
6) Kanungo A, Medeiros LJ, Abruzzo LV, et al.:Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol 19:25-33, 2006
 
7) Niitsu N, Okamoto M, Miura I, et al.:Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t (14;18) and 8q24/c-MYC translocations. Leukemia 23:777-783, 2009
 
8) Kikuchi A, Nakamura N, Kuze T, et al.:Characterization of de novo diffuse large B-cell lymphoma with a translocation of c-myc and immunoglobulin genes. Leuk Res 32:1176-1182, 2008
PubMed
P.260 掲載の参考文献
1) 中村直哉:16. バーキットリンパ腫/白血病. 最新・悪性リンパ腫アトラス, 菊池昌弘, 森茂郎編, 文光堂, 東京, 2004, pp190-196
 
2) Blum KA, Lozanski G, Byrd C:Adult Burkitt leukemia and lymphoma. Blood 104:3009-3020, 2004
 
3) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The non-Hodgkin's Lymphoma Classification Project. Blood 89:3909-3918, 1997
 
4) Lymphoma Study Group of Japanese Pathologists:The World Health Organization classification of malignant lymphomas in Japan:incidence of recently recognized entities. Pathol Int 50:696-702, 2000
 
5) 岡本昌隆, 新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO分類4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009
 
6) Bellan C, Lazzi S, Hummel M, et al.:Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-p ositive and EBV-negative Burkitt lymphomas. Blood 106:1031-1036, 2005
 
7) Hochberg D, Middeldorp JM, Catalina M, et al.:Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci USA 101:239-244, 2004
PubMed
8) Kian TC, Miriam T, Richard Q, et al.:Clinical characteris tics, prognostic factors and outcomes of Burkitt lymphoma in adult Asians. Leuk Lymphoma 49:824-827, 2008
 
9) Murphy SB:Classification, staging and results of treatment of childhood non-Hodgkin's lymphomas:dissimilarities from lymphomas in adults. Semin Oncol 7:332-339, 1980
PubMed
10) Magrath I, Adde M, Shad A, et al.:Adults and children with small non-cleaved-cell lymphoma have a similar excellent outocome when treated with the same chemotherapy regimen. J Clin Oncol 14:925-934, 1996
 
11) Mead GM, Sydes MR, Walewski J, et al.:An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma:results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13:1264-1274, 2002
PubMed
12) Freidberg JW, Ciminello L, Kelly J, et al.:Outcome of patients >age 40 with Burkitt lymphoma (BL) treated with aggressive chemotherapeutic regimens:results from the international Burkitt lymphoma cooperative group (abstr). Blood 106:#928, 2005
 
13) Thomas DA, Cortes J, O'Brien S, et al.:Hyper-CVAD program in Burkitt's type adult acute lymphoblastic leukemia. J Clin Oncol 17:2461-2470, 1999
 
14) Thomas DA, Faderl S, O'Brien S, et al.:Chemoimmunotherapy with hyper-CVAD plus rituxumab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569-1580, 2006
PubMed
15) Sweetenham JW Pearce R, Taghipour G, et al.:Adult Burkitt's and Burkitt like non-Hodgkin's lymphoma-Outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or relapse:Results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 14:2465-2472, 1996
 
16) Sweetenham JW, Proctor SJ, Blaise D, et al.:High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma:the EBMT experience. Lymphoma Working Party of the European Group for Bone Marrow Transplantation. Ann Oncol 5 (suppl 2):155-159, 1994
 
17) Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al.:An EBMT registry matched study of allogeneic stem cell transplant s for lymphoma:allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31:667-678, 2003
PubMed
18) Cortes J, Thomas D, Rios A, et al.:Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 94:1492-1499, 2002
PubMed
19) Kaplan LD, Lee JY, Ambinder RE et al.:Rituximab does not improve clinical outcome in randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-as sociated non Hodgkin lymphoma:AIDS-Malignancies Consortium Trial 010. Blood 106:1538-1543, 2005
 
20) Dunleavy K, Little RE Pittaluga S, et al.:A prospective study of dose-adjusted EPOCH with rituximab in adult with newly diagnosed Burkitt lymphoma:a regimen with high efficacy and low toxicity. Ann Oncol 19 (suppl 4):iv83, 2008
 
21) Leoncini L, Raphael M, Stein H, et al.:Burkitt Lymphoma. In:WHO Classification Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC press, Lyon, 2008, pp262-264
 
22) Bociek RG:Adult Burkitt's lymphoma. Clin Lymphoma 6:11-20, 2005
PubMed
Perkins AS, Friedberg JW:Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program:341-348, 2008
PubMed
i) Kluin PM, Harris NL, Stein H, et al.:B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC press, Lyon, 2008, pp265-266
 
P.265 掲載の参考文献
1) Zucca E:Extranodal lymphoma:a reappraisal. Ann Oncol 19 (suppl 4):iv77-iv80, 2008
 
2) 岡本昌隆,新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO分類第4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009
 
3) Zucca E, Conconi A, Cavalli F:Treatment of extranodal lymphomas. Best Pract Res Clin. Haematol 15:533-547, 2002
PubMed
4) Shenkier TN, Connoers JM:Primary extranodal non-Hodgkin's lymphomas. In:The Lymphomas, 2nd ed, ed by Canellos GP, Lister TA, Young B, Saunders, Philadelphia, 2006, pp325-347
 
5) Zucca E, Conconi A, Pedrinis E, et al., International Extranodal Lymphoma Study Group:Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 101:2489-2495, 200
 
6) Cortelazzo S, Rossi A, Oldani E, et al., International Extranodal Lymphoma Study Group (IELSG):The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. Br J Hematol 1181218-228, 2002
 
7) Cortelazzo S, Rossi A, Roggero E et al.:Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 10:1433-1440, 1999
 
8) Ryan G, Martinelli G, Kuper-Hommel M, et al., International Extranodal Lymphoma Study Group:Primary diffuse large B-cell lymphoma of the breast:prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 19:233-241, 2008
 
9) Zucca E, Conconi A, Mughal TI, et al., International Extranodal Lymphoma Study Group:Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 21:20-27, 2003
 
10) Ferreri AJ, Batchelor T, zucca E, et al., International Collaborative Group against Primary CNS Lymphomas. J Clin Oncol 21:1649-1650, 2003
 
i) Ferry JA:Extranodal lymphoma. Arch Pathol Lab Med 132:565-578, 2008
PubMed
P.273 掲載の参考文献
1) Isaacson PG, Chott A, Nakamura S, et al.:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In:WHO Classification of Tumours of Haematoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp214-217
 
2) Remstein ED, Dogan A, Einerson RR, et al.:The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 30:1546-1553, 2006
PubMed
3) Streubel B, Huber D, Wohrer S, et al.:Frequency of chromosomal aberrations involving MALT1 in mucosa-associated lym-phoid tissue lymphoma in patients with Sjogren's syndrome. Clin Cancer Res 10:476-480, 2004
 
4) Nathwani BN, Anderson JR, Armitage JO, et al.:Marginal zone B-cell lymphoma:A clinical comparison of nodal and mucosa-associated lymphoid tissue types. non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 17:2486-2492, 1999
PubMed
5) Traverse-Glehen A, Felman P, Callet-Bauchu E, et al.:A clinicopathologic study of nodal marginal zone B-cell lymphoma A report of 21 cases. Histopathology 48:162-173, 2006
PubMed
6) Wbtherspoon A, Chott A, Gascoyne RD, et al.:Lymphoma of the stomach. In:World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System, ed by Hamilton SR, Aaltonen LA, LARC Press, Lyon, 2000, pp57-61
 
7) Zamboni G, Franzin G, Scarpa A, et al.:Carcinoma-like signet-ring cells in gastric mucosa-associated lymphoid tissue (MAIT) lymphoma. Am J Surg Pathol 20:588-598, 1996
 
8) Gascoyne RD, Muller-Hermelink HK, Chott A, et al.:B-cell lymphoma of the small intestine. In:WHO Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System, ed by Hamilton SR, Aaltonen LA, IARC Press, Lyon, 2000, pp83-86
 
9) Muller-Hermelink HK, Chott A, Gascovne RD, et al.:B-cell lymphoma of the colon and rectum. In:WHO Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System, ed by Hamilton SR, Aaltonen LA, IARC Press, Lyon, 2000, pp139-141
 
10) Coupland SE, Klause L, Delecluse HJ, et al.:Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases. Opthalmology 105:1430-1441, 1998
 
11) Chan ALC, Chan JKC, Abbondanzo SL:Haematolymphoid tumours. In:WHO Classification of Tumours. Pathology and Genetics of Head an Neck Tumours, ed by Barnes L, Eveson JW, Reichart PA, et al., IARC Press, Lyon, 2005, pp277-280
 
12) Abbondanzo S, Aozasa K, Boerner S, et al.:Primary lymphoma and plasmacytoma. In:WHO Classification of Tumours. Pathology and Genetics of Tumours Endocrine Organs, ed by DeLellis RA, Lloyd RV, Heitz PU, et al., IARC Press, Lyon, 2004, pp109-111
 
13) Hsi ED, Singleton TB Svoboda SM, et al.:Characterization of the lymphoid infiltrate in Hashimoto thyroiditis by immunohistochemistry and polymerase chain reaction for immunoglobulin heavy chain gene rearrangement. Am J Pathol 110:327-333, 1998
 
14) Nicholson AG, Harris NL:Marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MAIT) type. In:WHO Classification of Tumours. Pathology and Genetics Of Tumours Lung, Pleura, Thymus, and Heart, ed by Travis WD, Brambilla E, Muller-Hermelink HK, et al, IARC Press, Lyon, 2004, pp88-90
 
15) Kempf W, Ralfkiaer E, Duncan L, et al.:Cutaneous marginal zone B-cell lymphoma. In:WHO Classification of Tumours. Pathology and Genetics. Skin Tumours, ed by LeBoit PE, Burg G, Weedon D, et al., IARC Press, Lyon, 2006, pp194-195
 
16) Harris NL, Isaacson PG, Grogan TM, et al.:Heavy chain diseases. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp196-199
 
P.281 掲載の参考文献
1) Dawson IM, Cornes JS, Morson BC:Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing Prognosis. Br J Surg 49:80-89, 1961
PubMed
2) Rohatiner A, d'Amore E Coiffier B, et al.:Report on a work-shop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 5:397-400, 1994
 
3) Mendelson RM, Fermoyle S:Primary gastrointestinal lymphomas:a radiological-pathological review. Part 1:Stomach, oesophagus and colon. Australas Radiol 49:353-364, 2005
PubMed
4) Inagaki H, Nakamura T, Li C, et al.:Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol 28:1560-1567, 2004
PubMed
5) Baens M, Maes B, Steyls A, et al.:The product of the t (11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. Am J Pathol 156:1433-1439, 2000
 
6) Schechter NR, Portlock CS, Yahalom J:Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 16:1916-1921, 1998
PubMed
7) Ruskone-Fourmestraux A, Delmer A, et al.:Gastro-intestinal lymphomas. Gastroenterol Clin Biol 2:2S81-2S90, 2006
 
8) Levy M, Copie-Bergman C, Gameiro C, et al.:Prognostic value of translocation t (11;18) in tumoral response of lowgrade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol 23:5061-5066, 2005
PubMed
9) Psyrri A, Papageorgiou S, Economopoulos T:Primary extranodal lymphomas of stomach:clinical presentation, diagnostic pitfalls and management. Ann Oncol 19:1992-1999, 2008
 
10) Martinelli G, Laszlo D, Ferreri AJ, et al.:Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 23:1979-1983, 2005
PubMed
11) Dickson BC, Serra S, Chetty R:Primary gastrointes tinal tractlymphoma:diagnosis and management of common neoplasms. Expert Rev Anticancer Ther 6:1609-1628, 2006
 
12) Wohrer S, Puspok A, Drach J, et al.:Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann Oncol 15:1086-1090, 2004
PubMed
13) Ishikura S, Tobinai K, Ohtsu A, et al.:Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II, diffuse large B-cell lymphoma of the stomach. Cancer Sci 96:349-352, 2005
 
14) Wong MT, Eu KW:Primary colorectal lymphomas. Colorectal Dis 8:586-591, 2006
PubMed
15) Cho MJ, Ha CS, Allen PK, et al.:Primary non-Hodgkin lymphoma of the large bowel. Radiology 205:535-539, 1997
PubMed
16) Tsang RW Gospodarowicz MK, Pintilie M, et al.:Stage I and II MAIT lymphoma:results of treatment with radiotherapy Int J Radiat Oncol Biol Phys 50:1258-1264, 2001
 
i) Psyrri A, Papageorgiou S, Economopoulos T:Primary extranodal lymphomas of stomach:clinical presentation, diagnostic pitfalls and management. Ann Oncol 19:1992-1999, 2008
 
P.285 掲載の参考文献
1) Freeman C, Berg JW Cutler SJ:Occurrence and prognosis of extranodal lymphomas. Cancer 29:252-260, 1972
PubMed
2) Derringer GA, Thompson LD, Frommelt RA, et al.:Malignant lymphoma of the thyroid gland:a clinicopathologic study of 108 cases. Am J Surg Pathol 24:623-639, 2000
PubMed
3) Widder S, Pasieka JL:Primary thyroid lymphomas. Curr Treat Options Oncol 5:307-313, 2004
PubMed
4) Niitsu N, Okamoto M, Nakamura N, et al.:Clinicopathologic correlations of stage I E/II E primary thyroid diffuse large B-cell lymphoma. Ann Oncol 18:1203-1208, 2007
 
5) Hans CR Weisenburger DD, Greiner TC, et al.:Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 103:275-282, 2004
 
6) Sato Y, Nakamura N, Nakamura S, et al.:Deviated VH4 immunoglobulin gene usage is found among thyroid mucosa-associated lymphoid tissue lymphomas, similar to the usage at o ther sites, but is not found in thyroid diffuse large B-cell lymphomas. Mod Pathol 19:1578-1584, 2006
 
7) DiBiase SJ, Grigsby PW, Guo C, et al.:Outcome analysis for stage I E and II E thyroid lymphoma. Am J Clin Oncol 27:178-184, 2004
 
8) Niitsu N, Okamoto M, Aoki S, et al.:Multicenter phase II study of the CyclOBEAP (CHOP-like+etoposide and bleo-mycin) regimen for patients with poor-prognosis aggressive lymphoma. Ann Hematol 85:374-380, 2006
 
i) Harrington KJ, Michalaki VJ, Vini L, et al.:Management of non-Hodgkin's lymphoma of the thyroid:the Royal Marsden Hospital experience. Br J Radiol 78:405-410, 2005
 
P.290 掲載の参考文献
1) Shenkier TN, Connoers JM:Primary extradonal non-Hodgkin's lymphomas. In:The Lymphomas, 2nd ed, ed by canellos GP, Lister TA, Young B, Saunders, Philadelphia, 2006, pp325-347.
 
2) Coupland SE, Krause L, Delecluse HJ, et al.:Lymphoproliferative lesions of the ocular adnexa:analysis of 112 cases. Ophthalmology 105:1430-1441, 1998
PubMed
3) Tanimoto K, Kaneko A, Suzuki S, et al.:Primary ocular adnexal MALT lymphoma:along-term follow-up study of 114 patients. Jpn J Clin Oncol 37:337-344, 2007
 
4) Ferry JA, Fung CY, Zukerberg L, et al.:Lymphoma of the ocular adnexa:A study of 353 cases. Am J Surg Pathol 31:170-184, 2007
PubMed
5) Lagoo AS, Haggerty C, Kim Y, et al.:Morphologic features of 115 lymphomas of the orbit and ocular adnexa categorized according to the World Health Organization classification:are marginal zone lymphomas in the orbit mucosa-associated lymphoid tissue-type lymphomas?Arch Pathol Lab Med 132:1405-1416, 2008
 
6) Remstein ED, Dogan A, Einerson RR, et al.:The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 30:1546-1553, 2006
PubMed
7) Streubel B, Huber D, Wohrer S, et al.:Frequency of chromosomal aberrations involving MALTI in mucosa-associated lymphoid tissue lymphoma in patients with Sjogren's syndrome. Clin Cancer Res 10:476-480, 2004
 
8) Tanimoto K, Sekiguchi N, Yokota Y, et al.:Fluorescence in situ hybridization (FISH) analysis of primary ocular adnexal MALT lymphoma. BMC Cancer 6:249, 2006
PubMed
9) Ferreri AJ, Guidoboni M, Ponzoni M, et al.:Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 96:586-594, 2004
PubMed
10) Chanudet E, Zhou Y, Bacon CM, et al.:Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J Pathol 209:344-351, 2006
PubMed
11) Decaudin D, Dendale R, Lumbroso-Le Rouic L:Treatment of mucosa-associated lymphoid tissue-type ocular adnexal lymphoma. Anticancer Drugs 19:673-680, 2008
 
12) Isobe K, Kagami Y, Higuchi K, et al.:A multicenter phase II study of local radiation therapy for stage IEA mucosa-associated lymphoid tissue lymphomas:apreliminary report from the Japan Radiation Oncology Group OAROG). Int J Radiat Oncol Biol Phys 69:1181-1186, 2007
 
13) Bessell EM, Henk JM, Wright JE, et al.:Orbital and conjunctival lymphoma treatment and prognosis. Radiother Oncol 13:237-244, 1988
PubMed
14) Esmaeli B, McLaughlin P, Pro B, et al.:Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol 20:709-714, 2009
PubMed
15) Matsuo T, Yoshino T:Long-term follow-up results of observation or radiation for conjunctival malignant lymphoma. Ophthalmology 111:1233-1237, 2004
PubMed
i) Sato Y, Ohshima K, Ichimura K, et al.:Ocular adnexal IgG4-related disease has uniform clinicopathology. Pathol Int 8:465-470, 2008
PubMed
P.294 掲載の参考文献
1) Wiseman C, Liao KT:Primary lymphoma of the breast. Cancer 29:1705-1712, 1972
PubMed
2) Lopez-Guillermo A, Colomo L, Jimenez M, et al.:Diffuse large B-cell lymphoma:clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 23:2797-2804, 2005
PubMed
3) Niitsu N, Okamoto M, Nakamine H, et al.:Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma. Leule Res 32:1837-1841, 2008
PubMed
4) Ryan G, Martinelli G, Kuper-Hommel M, et al.:Primary diffuse large B-cell lymphoma of the breast:prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 19:233-241, 2008
 
5) Leoncini L, Raphael M, Stein H, et al.:Burkitt lympoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp262-264
 
6) Yoshida S, Nakamura N, Sasaki Y, et al.:Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. Mod Pathol 18:398-405, 2005
 
7) Fruchart C, Denoux Y, Chasle J, et al.:High grade primary breast lymphoma:is it a different clinical entity?Breast Cancer Res Treat 93:191-198, 2005
PubMed
8) Ganjoo K, Advani R, Mariappan MR, et al.:Non-Hodgkin lymphoma of the breast. Cancer 110:25-30, 2007
PubMed
9) Aviles A, Castafieda C, Neri N, et al.:Rituximab and dose dense chemotherapy in primary breast lymphoma. Haematologica 92:1147-1148, 2007
 
10) Wong WW, Schild SE, Halyard MY, et al.:Primary non-Hodgin lymphoma of the breast:The Mayo Clinic experience. J Surg Oncol 80:19-25, 2002
 
11) Au WY, Chan AC, Chow LW et al.:Lymphoma of the breast in Hong Kong Chinese. Hematol Oncol 15:33-38, 1997
 
12) Validire P, Capovilla M, Asselain B, et al.:Primary breast non-Hodgkin's lymphoma:a large single center study of initial characteristics, natural history, and prognostic factors. Am J Hematol 84:133-139, 2009
PubMed
P.297 掲載の参考文献
1) Zucca E, Conconi A, Mughal TI, et al.:Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 21:20-27, 2003
 
2) Marx A, Woodward PJ:Lymphoma and plasmacytoma of the testis and paratesticular tissues. In:World Health Organization Classification of Tumours. Pathology and Genetics of the Urina ry Sγstem and Male Genital Organs, ed by Eble JN, Sauter G, Epstein JE, et al., IARC Press, Lyon, 2004, pp263-264
 
3) Mazzu D, Jeffrey RB Jr, Ralls PW:Lymphoma and leukemia involving the testicles:findings on gray-scale and color dop-pler sonography AIR Am J Roentgenol 164:645-647, 1995
 
4) Bacon CM, Ye H, Diss TC, et al.:Primary follicular lymphoma of the testis and epididymis in adults. Am J Surg Pathol 31:1050-1058, 2007
PubMed
5) Pileri SA, Sabattini E, Rosite P, et al.:Primary follicular lymphoma of the testis in childhood:an entity with peculiar clinical and molecular characteristics. J Clin Pathol 55:684-688, 2002
 
6) Al-Abbadi MA, Hattab EM, Tarawneh MS, et al.:Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup:A study of 18 cases. Mod Pathol 19:1521-1527, 2006
 
7) Vitolo U, Zucca E, Chiappella A, et al.:Primary diffuse large B-cell lymphoma of the testis improved outcome with rituximab-CHOP with CNS and contralateral testis prophylaxis. final results of IELSG 10 Study. Haematologica 93:abstract#401, 2008
 
P.304 掲載の参考文献
1) Desai S, Jambhekar NA, Soman CS, et al.:Primary lymphoma of bone:a clinicopathologic study of 25 cases reported over 10 years. J Surg Oncol 46:265-269, 1991
 
2) Mulligan ME, McRac GA, Murphey MD:Imaging features of primary lymphoma of bone. AJR Am J Roentgenol 173:1691-1697, 1999
 
3) Unni KK, Hogendoorn PCW:Malignant lymphoma. In:World Health Organization Classification of Tumours. Pathology and Genetics of Tumours Of Soft Tissue and Bone, ed by Fletcher CD, Unni KK, Mertens E Lyon, pp306-308, 2002
 
4) Vincent JM, Ng YY, Norton AJ, et al.:Case report:Primary lymphoma of bone-MR Imaging appearances with pathological correlation. Clin Radiol 45:407-409, 1992
 
5) 岡本昌隆, 新津望, 三浦偉久男ほか:2000例を越える連続録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO分類第4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009
 
6) Durr HR, Muller PE, Hiller E, et al.:Malignant lymphoma of bone. Arch Orthop Trauma Surg 122:10-16, 2002
PubMed
7) Gianelli U, Patriarca C, Moro A, et al.:Lymphomas of the bone:A pathological and clinical study of 54 cases. Int J Surg Pathol 10:257-266, 2002
 
8) Marshall DT, Amdur RJ, Scarborough MT, et al.:Stage I E pri-mary non-Hodgkin's lymphoma of bone. Clin Orthop 405:216-222, 2002
 
9) Zinzani PL, Carrillo G, Ascani S, et al.:Primary bone lymphoma:experience with 52 patients. Haematologica 88:280-285, 2003
PubMed
10) Krishnan A, Shirkhoda A, Tehranzadeh J, et al.:Primary Bone Lymphoma:Radiographic-MR imaging correlation. Radiographics 23:1371-1383, 2003
PubMed
11) Ozdemirli M, Mankin HJ, Aisenberg AC, et al.:Hodgkin's disease presenting as a solitary bone tumor. A report of four cases and review of the literature. Cancer 77:79-88, 1996
PubMed
12) Heyning FH, Hogendoorn PC, Kramer MH, et al.:Primary non-Hodgkin's lymphoma of bone:aclinicopathological inves-tigation of 60 cases. Leukemia 12:2094-2098, 1999
 
13) Ueda T, Aozasa K, Ohsawa M, et al.:Malignant lymphomas of bone in Japan. Cancer 64:2387-2392, 1989
PubMed
14) Ostrowski ML, Inward CY, Strickler JG, et al.:Osseous Hodg-kin disease. Cancer 85:1166-1178, 1999
 
15) Chan JK, Ng CS, Hui PK, et al.:Anaplastic large cell Ki-1 lymphoma of bone. Cancer 68:2186-2191, 1991
PubMed
16) Misgeld E, Wehmeier A, Kromeke O, et al.:Primary non-Hodgkin's lymphoma of bone:three cases and a short review of the literature. Ann Hematol 82:440-443, 2003
 
17) Heyning FH, Hogendoorn PC, Kramer MH, et al.:Primary non-Hodgkin's lymphoma of bone:a clinicopathological investigation of 60 cases. Leukemia 13:2094-2098, 1999
 
18) Remadan MK, Shenkier T, Sehn LH, et al.:A clinicopathological retrospective study of 131 patients with primary bone lymphoma:a population-based study of successively treated cohorts from the British Colombia Cancer Agency. Ann Oncol 18:129-135, 2007
 
P.310 掲載の参考文献
1) Isaacson PG, Norton AJ:Extranodal lymphomas, Churchill Livingstone, New York, 1994
 
2) Freeman C, Berg JW Cutler SJ:Occurrence and prognosis of extranodal lymphomas. Cancer 29:252-260, 1972
PubMed
3) Ferraro P, Trastek VE Adlakha H, et al.:Primary non-Hodgkin's lymphoma of the lung. Ann Thorac Surg 69:993-997, 2000
 
4) 岡本昌隆, 新津望, 三浦偉久男ほか:2000 例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO分類第4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009
 
5) Zinzani PL, Tani M, Gabriele A, et al.:Extranodal marginal zone B-cell lymphoma of MALT-type of the lung:Single center experience with 12 patients. Leule Lymphoma 44:821-824, 2003
PubMed
6) Wannesson L, Cavalli E Zucca E:Primary pulmonary lymphoma:current status. Clin Lymphoma Myeloma 6:220-227, 2005
 
7) King LJ, Padley SP, Wotherspoon AC, et al.:Pulmonary MALT lymphoma:imaging findings in 24 cases. Eur Radiol 10:1932-1938, 2000
PubMed
8) Cadranel J, Wislez M, Antoine M:Primary pulmonary lymphoma. Eur Respir J 20:750-762, 2002
PubMed
9) Kostakoglu L, Coleman M, Leonard JP, et al.:PET predict s prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43:1018-1027, 2002
PubMed
10) 稲垣宏, 岡部光邦:肺のリンパ腫各論/2. 臓器別リンパ腫の特徴 悪性リンパ腫のすべて. 血液・腫瘍科49 (suppl 4):665-671, 2004
 
11) Akagi T, Motegi M, Tamur A, et al.:A novel gene, MALT1 at 18q21, is involved in t (11;18) (q21;q21) found in low-g rade B-cell lymphoma of mucosa-associated lymphoid tissue. Onco-gene 18:5785-5794, 1999
 
12) Ye H, Liu H, Attygalle A, et al.:Variable frequencies of t(11;18) (q21;q21) in MALT lymphomas of different sites:significant association with CagA strains of H. pylori in gastric MALT lymphoma. Blood 102:1012-1018, 2003
PubMed
13) Rosenwald A, Ott G, Stilgenbauer S, et al.:Exclusive detection of the t (11:18) (q21;q21) in extranodal marginal zone B cell lymphoma (MZBL) of MALT type in contrast of other MZBL and extranodal large B cell lymphomas. Am J Pathol 155:1817-1821, 1999
 
14) Zucca E, Conconi A, Pedrinis E, et al.:Nongastric mar ginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 101:2489-2495, 2003
 
15) Coldier JE Chailleux E, Lauque D, et al.:Primary pulmonary lymphomas. A clinical study of 70 cases in nonimmunocompro-mised patients. Chest 103:201-208, 1993
 
16) Conconi A, Martinelli G, Thieblemont C, et al.:Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 102:2741-2745, 2003
PubMed
17) Jager G, Neumeister P, Brezinschek R, et al.:Treatment of extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue type with cladribine:a phase II study. J Clin Oncol 20:3872-3877, 2002
PubMed
P.314 掲載の参考文献
1) Ferry JA, Young RH:Malignant lymphoma, pseudolymphoma, and hematopoietic disorders of the female genital tract. Pathol Annu 26:227-263, 1991
PubMed
2) Freeman C, Berg JW, Cutler SJ:Occurrence and prognosis of extranodal lymphomas. Cancer 29:252-260, 1972
PubMed
3) Chorlton I, Norris HJ, King FM:Malignant reticuloendothelial disease involving the ovary as a primary manifestation:a series of 19 lymphomas and 1 granulocytic sarcoma. Cancer 34:397-407, 1974
 
4) 岡本昌隆,新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度-WHO分類第4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009
 
5) Isaacson PG, Norton AJ:Malignant lymphoma of the urogenital tract. In:Extranodal lymphomas, ed by Isaacson PG, Norton AJ, Churchill Livingstone, Edinburgh, 1994, pp273-287
 
6) Rotmensch J, Woodruff JD:Lymphoma of the ovary:report of twenty new cases and update of previous series. Am J Obstet Gynecol 143:870-875, 1982
PubMed
7) Andrews SJ, Hernandez E, Woods J, et al.:Burkitt's-like lymphoma presenting as a gynecologic tumor. Gynecol Oncol 30:131-136, 1988
 
8) Harris NL, Scully RE:Malignant lymphoma and granulocytic sarcoma of the uterus and vagina. a clinicopathologic analysis of 27 cases. Cancer 53:2530-2545, 1984
 
9) Osborn BM, Robboy SJ:Lymphomas or leukemia presenting as ovarian tumors. An analysis of 42 cases. Cancer 52:1933-1943, 1983
PubMed
10) Chorlton I:Malignant lymphoma of the female genital tract and ovaries. In:Haines and Taylor obstetrical and gynaecological pathology, ed by Fox H, Churchill Livingstone, Edinburgh, 1987, p737
 
11) Jaffe ES:Surgical Pathology of the lymph nodes and related organs, W B. Saunders, Philadelphia, 1985
 
12) Dimopoulos MA, Dariani D, Pugh W, et al.:Primary ovarian non-Hodgkin's lymphoma:Outcome after treatment with combination chemotherapy Gyneco Oncol 64:446-450, 1997
 
13) Lopez TM, Hagemeister FB, McLaughlin B et al.:Small noncleaved cell lymphoma in adults:superior results for stage I-III disease. J Clin Oncol 8:615-622, 1990
 
14) Vang R, Medeiros LJ, Warnke RA, et al.:Ovarian non-Hodgkin's lymphoma:aclinicopathologic study of eight pri-mary cases. Mod Pathol 14:1093-1099, 2001
 
15) Chorlton I, Karnei RE King FM, et al.:Primary malignant reticuloendotherial disease involving the vagina cervix and cor-pus uteri. Obstet Gynecol 44:735-748, 1974
 
16) Khoury GG, Robinson A:Lymphoma of uterine cervix. Eur J Surg Oncol 15:65-67, 1989
PubMed
P.317 掲載の参考文献
1) Vega F Lin P, Medeiros LJ:Extranodal lymphomas of the head and neck. Ann Diagn Pathol 9:340-350, 2005
PubMed
2) Cuadra-Garcia I, Prouly GM, Wu CL, et al.:Sinonasal lympho-ma:aclinicopathologic analysis of 58 cases from the Massa-chusetts General Hospital. Am J Surg Pathol 23:1356-1369, 1999
 
3) Cheung MM, Chan JK, Lau WH, et al.:Primary non-Hodgkin's lymphoma of the nose and nasopharynx:clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 16:70-77, 1998
PubMed
4) Hill QA, Owen RG:CNS prophylaxis in lymphoma:WHO Classification to target and what therapy to use. Blood Reviews 20:319-332, 2006
 
5) Kim GE, Koom WS, Yang WI, et al.:Clinical relevance of three subtypes of primary sinonasal lymphoma characterized by immunophenotypic analysis. Head Neck 26:584-593, 2004
PubMed
6) Oprea C, Cainap C, Azoulay R, et al.:Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses:a report of 14 cases. Br J Haematol 131:468-471, 2005
 
P.322 掲載の参考文献
1) d'Amore E Brincker H, Christensen BE, et al.:Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group. Ann Oncol 3:379-386, 1992
 
2) Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients:The non-Hodgkin's Lymphoma Classification Prolect. Ann Oncol 8:973-978, 1997
 
3) Thieblemont C, Coiffier B:Lymphoma in older patients. J Clin Oncol 25:1916-1923, 2007
PubMed
4) Van Zant G, Liang Y:The role of stem cells in aging. Exp Hematol 31:659-672, 2003
PubMed
5) Mori M, Niitsu N, Takagi T, et al.:Reduced-dose chop therapy for elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 41:359-366, 2001
PubMed
6) Niitsu N, Iijima K:Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive on-Hodgkin's lymphoma in elderly patients:a prospective study Ann Hematol 80:602-606, 2001
PubMed
7) Pfreundschuh M, Trumper L, Kloess M, et al.:Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas:results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004
 
8) Feugier P, Van Hoof A, Sebban C, et al.:Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005
 
9) Habermann TM, Weller EA, Morrison VA, et al.:Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006
PubMed
10) Pfreundschuh M, Schubert J, Ziepert M, et al.:Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+B-cell lymphomas arandomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116, 2008
PubMed
11) Boehme V, Schmitz N, Zeynalova S, et al.:CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab:An analysis of patients treated in the RICOVER-60 tri al of the German high-grade non-Hodgkin lymphoma study group (DSHNHL). Blood 113:3896-3902, 2009
PubMed
12) Feugier P, Virion JM, Tilly H, et al.:Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma:influence of rituximab. Ann Oncol 15:129-133, 2004
PubMed
13) Lugtenburg PJ, Sonneveld P:Treatment of diffuse large B-cell lymphoma in the elderly:strategies integrating oncogeriatric themes. Curr Oncol Rep 10:412-419, 2008
PubMed
P.329 掲載の参考文献
1) WHO Claxxification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL,et al.,IARC Press, Lyon,2008
 
2) A clinical evaluation of the International Lymphoma Stydy Group Classification non-Hodgkin's lymphoma. The NonHodgkin's Lymphoma Classification Project. Blood 89:3909-3918,1997
 
3) Vose J,Armitage J,Weisenburger D, et al.:International peripheral T-cell and natural Killer/T-cell lymphoma study:phathology findings and clinical findings. J Clin Oncol 26:4124-4130,2008
 
4) Aoki R, Karube K,Sugita Y,et al.:Distribution of malignant lymphoma in Japan : analysis of 2260 cases,2001-2006.Pathol Int 58:174-182,2008
PubMed
P.334 掲載の参考文献
1) Pilozzi E, Pulford K, Jones M, et al.:Co-experssion on CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol 186:140-143, 1998
 
2) Paietta E, Ferrando AA, Neuberg D, et al.:Activating FLT3 mutations in CD117/KIT+T-cell acute lymphoblastic leukemias. Blood 104:558-560, 2004
 
3) Pilozzi E, Muller-Hermelink HK, Falini B, et al.:Gene rearrangements in T-cell lymphoblastic lymphoma. J Pathol 188:267-270, 1999
 
4) Okuda T, Fisher R, Downing JR:Moelecular diagnostics in pediatric acute lymphoblastic leukemia. Mol Diagn 1:139-151, 1996
 
5) Katsuno M, Abe Y, taguchi F, et al.:CD7+stem cell leukemia/lymphoma. Features of a subgroup without circulating blast cells. Cancer 72:99-104, 1993
PubMed
6) Chaperot L, Bendriss N, Manches O, et al.:Identification of leukemic counterpart of the plasmacytoid dendrictic cells. Blood 97:210-3217, 2001
 
7) Suzuki R, Yamamoto K, Seto M, et al.:CD7+and CD56+myeloid/natural killer cell precursor acute leukemia:a distinct hematolymphoid disease entity. Blood 90:2417-2428, 1997
PubMed
8) Chan JKC, Jaffe ES, Ralfkiaer E:Blastic NK-cell lymphoma. In:WHO classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, ed by Jaffe ES, Harris NL, Stein H, et al., IARC Press, Lyon, 2001, pp214-215
 
9) Petrella T, Comeau MR, Maynadie M, et al.:"Agranula CD4+ CD56+hematodermic neoplasm" (blastic NK-cell lymphoma) originates from a population of CD56+precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 26:852-862, 2002
PubMed
10) Herling M, Teitell MA, Shen RR, et al.:TCL1 expression in plasmacytoid dendrictic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood 101:5007-5009, 2003
 
11) Herling M, Jones D:CD4+/CD56+hematodermic tumor:the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol 127:687-700, 2007
PubMed
12) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al.:LARC Press, Lyon, 2008
 
i) Millot E Suciu S, Philippe N, et al.:Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia:Result of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Clin Oncol 19:1935-1942, 2001
 
P.342 掲載の参考文献
1) Delsol G, Jaffe ES, Falini B, et al.:Anaplastic large cell lymphoma (ALCL), ALK-positive. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp312-316
 
2) Shiota M, Nakamura S, Ichinohasama R, et al.:Anaplastic large cell lymphomas expressing the novel chimeric protein P80NPM/ALK:a distinct clinicopathologic entity Blood 86:1954-1960, 1995
PubMed
3) Nakamura S, Shiota M, Nakagawa A, et al.:Anaplastic large cell lymphoma:a distinct molecular pathologic entity:a reappraisal with special reference to p80NPM/ALK expression. Am J Surg J Pathol 21:1420-1432, 1997
 
4) Suzuki R, Kagami Y, Takeuchi K, et al.:Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96:2993-3000, 2000
PubMed
5) Mason DY, Campo E, Harris NL, et al.:Anaplastic large cell lymphoma, ALK-negative. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp317-319.
 
6) Asano N, Suzuki R, Matsuo K, et al.:Cytotoxic molecule expression is predictive of prognosis in Hodgkin's-like anaplastic large cell lymphoma. Histopathology 50:705-715, 2007
PubMed
7) Ralfkiaer E, Willemze R, Pauli M, et al.:Primary cutaneous CD30-positive T-cell lymphoproliferative disorders, In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp300-301
 
P.348 掲載の参考文献
1) Stein H, Mason DY, Gerdes J, et al.:The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue:evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blodd 66:848-858, 1985
 
2) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008
 
3) Savage KJ, Harris NL, Vose JM, et al.:ALK-Lanaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified:report from the International Peripheral T-Cell Lymphoma Project. Blood 111:5496-5504, 2008
 
4) Stein H, Foss HD, Durkop H, et al.:CD30+ anaplastic large cell lymphoma:a review of its histopathologic, genetic, and clinical features. Blood 496:3681-3695, 2000
 
5) Bonzheim I, Geissinger E, Roth S, et al.:Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell reptor signaling. Blood 104:3358-3360, 2004
 
6) ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al.:ALK-negative systemic anaplastic large cell lymphoma:differential diagnostic and prognostic aspects a review. J Pathol 200:4-15, 2003
PubMed
7) Falini B, Pulford K, Pucciarini A, et al.:Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 94:3509-3515, 1999
PubMed
8) Fiorani C, Vinci G, Sacchi S, et al.:Primary systemic anaplastic large-cell lymphoma (CD30+):advances in biology and current therapeutic approaches. Clin Lymphoma 2:29-37, 2001
PubMed
9) Suzuki R, Kagami Y, Takeuchi K, et al.:Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. . Blood 96:2993-3000, 2000
PubMed
10) Falini B, Pileri S, Zinzani PL, et al.:ALK+lymphoma:clinicopathological findings and outcome. Blood 93:2697-2706, 1999
PubMed
11) Gascoyne RD, Aoun P Wu D, et al.:Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93:3913-3921, 1999
PubMed
12) Tilly H, Gaulard P, Lepage E, et al.:Primary anaplastic large-cell lymphoma in adults:clinical presentation, immunophenotype, and outcome. Blood 90:3727-3734, 1997
PubMed
13) Jagasia M, Morgan D, Goodman S, et al.:Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 45:2261-2267, 2004
PubMed
14) Fanin R, Ruiz de Elvira MC, et al.:Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma:analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 23:437-442, 1999
 
15) Deconinck E, Lamy T Foussard C, et al.:Autologous stem cell transplantation for anaplastic large-cell lymphomas:results of a prospective trial. Br J Hematol 109:736-742, 2000
 
16) Fanin R, Silvestri F, Geromin A, et al.:Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult:sequential intensive treatment with the F-MACHOP regimen (+/-radiotherapy) and autologous bone marrow transplantation. Blood 87:1243-1248, 1996
 
17) Rassidakis GZ, Goy A, Medeiros LJ, et al.:Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma. Clin Cancer Res 9:2213-2220, 2003
PubMed
18) Schlette EJ, Medeiros LJ, Goy A, et al.:Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 22:1682-1688, 2004
PubMed
P.355 掲載の参考文献
1) Suchi T:Atypical hyperplasia of lymph nodes with poor prognosis:immunological characterization of the proliferating cells. Res Adv RES Res 18:124-133, 1978
 
2) Shimoyama M, Minato K, Saito H, et al.:Immunoblastic lymphadenopathy (IBL)-like T-cell lymphoma. Jpn J Clin Oncol 9 (suppl):347-356, 1979
 
3) Dogan A, Attygalle AD, Kyriakou C:Angioimmunoblastic T-cell lymphoma. Br J Haematol 121:681-691, 2003
PubMed
4) Dupuis J, Boye K, Martin N, et al.:Expression o f CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL):a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 30:490-494, 2006
 
5) de Leval L, Rickman DS, Thielen C, et al.:The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109:4952-4963, 2007
PubMed
6) Jones D, Jorgensen JL, Shahsafaei A, et al.:Characteristic proliferations of reticular and dendritic cells in angioimmunooblastic lymphoma. Am J Surg. Pathol 22:956-964, 1998
PubMed
7) Anagnostopoulos I, Hummel M, Finn T, et al.:Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 80:1804-1812, 1992
PubMed
8) Zettl A, Lee SS, Rudiger T, et al.:Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol 117:368-379, 2002
PubMed
9) Quintanilla-Martinez L, Fend E Moguel LR, et al.:Peripheral T-cell lymphoma with Reed-Sternberg-like cells of B-cell phenotype and genotype associated with Epstein-Barr virus infection. Am J Surg Pathol 23:1233-1240, 1999
 
P.361 掲載の参考文献
1) Dogan A, Gaulard P, Jaffe ES, et al.:Angioimmunoblastic T-cell lymphoma. In:WHO Classification of Tumours of Haemapoietic and Lynzphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL et al., IARC Press, Lyon, 2008
 
2) 岡本昌隆, 新津望, 三浦偉久男ほか:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO分類第4版もふまえて-. 日本リンパ網内系雑誌 49:86, 2009
 
3) Mourad N, Mounier N, Briere J, et al,:Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 111:4463-4470, 2008
 
4) Dogan A, Attygalle AD, Kyriakou C:Angioimmunoblastic T-cell lymphoma. Br J Haematol 121:681-691, 2003
PubMed
5) Niitsu N, Okamoto M, Nakamine H, et al.:Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol 26:152-158, 2008
PubMed
6) Went P, Agostinelli C, Gallamini A, et al.:Marker expre ssion in peripheral T-cell lymphoma:a proposed clinical-pathologic prognostic score. J Clin Oncol 24:2472-2479, 2006
 
7) Dupuis J, Boye K, Martin N, et al.:Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL):a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 30:490-494, 2006
PubMed
8) Dunleavy K, Wilson WH, Jaffe ES:Angioimmunoblastic T cell lymphoma:pathobiological insights and clinical implications. Curr Opin Hematol 14:348-353, 2007
PubMed
9) Pangalis GA, Moran EM, Rappaport H:Blood and bone marrow findings in angioimmunoblastic lymphadenopathy Blood 51:71-83, 1978
PubMed
10) Siegert W, Agthe A, Griesser H, et al.:Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study Kiel Lymphoma Study Group. Ann Intern Med 117:364-370, 1992
 
11) Sallah S, Gagnon GA:Angioimmunoblastic lymphad enopathy with dysproteinemia:emphasis on pathogenesis and treatment. Acta. Haematol 99:57-64, 1998
 
12) Pautier B Devidas A, Delmer A, et al.:Angioimmunoblastic-like T-cell non Hodgkin's lymphoma:outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 32:545-552, 1999
PubMed
13) Schetelig J, Fetscher S, Reichle A, et al.:Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 88:1272-1278, 2003
PubMed
14) Kyriakou C, Canals C, Goldstone A, et al.:High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma:Complete Remission at Transplantation is the major determinant of Outcome Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26:218-224, 2008
 
15) Rodriguez J, Conde E, Gutierrez A, et al.:Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation:the GELTAMO experience. Eur J Haematol 78:290-296, 2007
PubMed
16) Advani R, Horwitz S, Zelenetz A, et al.:Angioimmunoblastic Tcell lymphoma:treatment experience with cyclosporine. Leuk Lymphoma 48:521-525, 2007
PubMed
17) Siegert W, Nerl C, Meuthen I, et al.:Recombinant human interferon-alpha in the treatment of angioimmunoblastic lymphadenopathy:results in 12 patients. Leukemia 5:892-895, 1991
PubMed
18) Halene S, Zieske A, Berliner N:Sustained remission fr m angioimmunoblastic T-cell lymphoma induced by alemtuzumab. Nat Clin Pract Oncol 3:165-168; quiz 169, 2006
 
19) Gallamini A, Zaja E Patti C, et al.:Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma:results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316-2323, 2007
 
20) Bruns I, Fox E Reinecke P, et al.:Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. . Leukemia 19:1993-1995, 2005
 
21) Aguiar Bujanda D:Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Ann Oncol 19:396-397, 2008
 
22) Siegert W, Nerl C, Agthe A, et al.:Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma:prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol 6:659-664, 1995
 
23) Schlegelberger B, Zwingers T Hohenadel K, et al.:Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type. J Clin Oncol 14:593-599, 1996
 
24) Iannitto E, Ferreri AJ, Minardi V, et al.:Angioimmunoblastic T-cell lymphoma. Crit Rev Oncol Hematol 68:264-271, 2008
PubMed
25) Zhao WL, Mourah S, Mounier N, et al.:Vascular endothelialgrowth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest 84:1512-1519, 2004
 
P.362 掲載の参考文献
i) Steeg PS, Bevilacqua G, Kopper L, et al:Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 80:200, 1988
PubMed
ii) Niitsu N, Honma Y, Iijima K, et al:Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma. Leukemia 17:196, 2003
 
P.369 掲載の参考文献
1) Lennert K, Feller AC:Histopathology of Non-Hodgkin's Lymphoma (Based on the Updated Kiel Classification), Springer-Verlag, Berlin, 1992
 
2) Rizvi MA, Evens AM, Tallman MS, et al.:T-cell non-Hodg-kin lymphoma. Blood 107:1255-1264, 2006
 
3) Suchi T, Lennert K, Tu LY, et al.:Histopathology and immuno-histochemistry of peripheral T-cell lymphoma:a proposal for their classification. J Clin Pathol 40:995-1015, 1987
 
4) Streubel B, Vinatzer U, Willheim M, et al.:Novel t(5;9) (q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 20:313-318, 2006
PubMed
5) Yamashita Y, Nakamura S, Kagami Y, et al.:Lennert's lymphoma:A variant of cytotoxic T-cell lymphoma? Am J Surg Pathol 24:1627-1633, 2000
 
P.377 掲載の参考文献
1) Pileri SA, Weisenburger DD, Sng I, et al,:Peripheral T-ell lymphoma, not otherwise specified. In:WHO Classifiationof Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC Press, Lyon, 2008, pp306-308
PubMed
2) de Leval L, Bisig B, Thielen C, et al.:Molecular classification of T-cell lymphomas. Crit Rev Oncol Hematol, 2009 (in press)
 
3) Rodriguez-Abreu D, Filho VB, Zucca E:Peripheral T-cell lymphomas, unspecified (or not otherwise specified):a review. Hematol Oncol 26:8-20, 2008
PubMed
4) Niitsu N, Okamoto M, Nakamine H, et al.:Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol 26:152-158, 2008
PubMed
5) Vose J, Amlitage J, Weisenburger D, et al.:International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008
PubMed
6) Rodriguez J, Gutierrez A, Martinez-Delgado B, et al.:Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. Crit Rev Oncol Hematol, 2008 (in press)
 
7) Fisher RI, Gaynor ER, Dahlberg S, et al.:Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
PubMed
8) Schmitz N, Ziepert M, Nickelsen M, et al.:T-cell lymphomas in studies of the German High-Grade non-Hodgkin's Lymphoma Study Group (DSHNHL) (abstr), Ann Oncol 9 (supp 4):94a, 2008
 
9) Gressin R, Peoch M, Deconinck E, et al.:The VIP-ABVD Regimen is not superior to the CHOP 21 for the treatment of non epidermotropic peripheral T-cell lymphoma. Final resul ts of the:'LTP95"protocol of the GOELAMS (abstr). Blood 108:2464, 2006
PubMed
10) Sung HJ, Kim SJ, Seo HY, et al.:Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B:single institutional study Br J Hematol 134:45-53, 2006
 
11) Martinez-Delgado B, Cuadros M, Honrado E, et al.:Differential expression of NF-κB pathway genes among peripheral T-cell lymphomas. Leukemia 19:2254-2263, 2005
 
12) Greer JP:Therapy of peripheral T/NK neoplasms. Hematology Am Soc Hematol Educ Program:331-337, 2006
PubMed
13) Tilly H, Lepage E, Coiffier B, et al.:Intensive conventional (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289, 2003
PubMed
14) Corradini P, Tarella C, Zallio E et al.:Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20:1533-1538, 2006
PubMed
15) Reimer P, Schertlin T, Rudiger T, et al.:Myeloablative radiohemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas:first results of a prospective multicenter study Hematol J 5:304-311, 2004
 
16) Mounier N, Gisselbrecht C, Briere J, et al.:All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation:a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 15:1790-1797, 2004
PubMed
17) Gisselbrecht C, Lepage E, Molina T, et al.:Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20:2472-2479, 2002
PubMed
18) Reimer P, Ruediger T, Weissinger F, et al.:Different outcome for angioimmunoblastic T-cell lymphoma (AIL) and peripheral T-cell lymphoma unspecified (PTCL-U) following upfront autologous stem cell transplantation (abstr). Blood 108:5431, 2006
 
19) d'Amore E Relander T, Lauritzsen G, et al.:Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-cell lymphomas (PTCL)-a phase II study of the Nordic Lymphoma Group (NLG) (abstr). Blood 108:401, 2006
 
20) Mercadal S, Briones J, Xicoy B, et al.:Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19:958-963, 2008
 
21) Rodriguez J, Conde E, Gutierrez A, et al.:Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma:a prospective study from The Gel-Tamo Study Group. Eur J Hematol 79:32-38, 2007
 
22) Reimer R Rudiger T, Geissinger E, et al.:Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas:results of a prospective multicenter study J Clin Oncol 27:106-113, 2009
 
23) Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et al.:Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 134:202-207, 2006
 
24) Corradini P, Dodero A, Zallio F, et al.:Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22:2172-2176, 2004
 
25) Le Gouill S, Milpied N, Buzyn A, et al.:Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults:a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26:2264-2271, 2008
PubMed
26) Gallamini A, Stelitano C, Calvi R, et al.:Peripheral T-cell lymphoma unspecified (PTCL-U):a new prognostic model from a retrospective multicentric clinical study Blood 103:2474-2479, 2004
 
27) Savage KJ:Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program:280-288, 2008
PubMed
28) Niitsu N, Nakamine H, Okamoto M, et al.:Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma. Br J Haematol 123:621-630, 2003
PubMed
P.378 掲載の参考文献
i) Niitsu N, Kohri M, Higashihara M, et al.:Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci 98:109-112, 2007
PubMed
P.384 掲載の参考文献
1) Lymphoma Study Group of Japanese Pathologists:The world health organization classification of malignant lymphomas in Japan:incidence of recently recognized entities. Pathol Int 50:696-702, 2000
 
2) Au WY, Ma SY, Chim CS, et al.:Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme:a single center experience of 10 years. Ann Oncol 16:206-214, 2005
 
3) Arber DA, Weiss LM, Albujar PF, et al.:Nasal lymphomas in Peru. High incidence of T-cell immunophenotype and Epstein-Barr virus infection. Am J Surg Pathol 17:392-399, 1993
PubMed
4) Elenitoba-Johnson KS, Zarate-Osorno A, Meneses A, et al.:Cytotoxic granular protein expression, Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico. Mod Pathol 11:754-761, 1998
PubMed
5) Tien HF, Su IJ, Tang JL, et al.:Clonal chromosomal abnormalities as direct evidence for clonality in nasal T/natural killer cell lymphomas. Br J Haematol 97:621-625, 1997
PubMed
6) Nakashima Y, Tagawa H, Suzuki R, et al.:Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia:different genomic alteration patterns of aggressive NK-cell leukemia and extranodal NK/T-cell lymphoma, nasal type. Genes Chromosomes Cancer 44:247-255, 2005
PubMed
P.394 掲載の参考文献
1) Chan JKC, Quintanilla-Martinez L, Ferry JA, et al.:Extranodal NK/T-cell lymphoma, nasal type. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed by Swerdlow SH, Campo E, Harris NL, et al., IARC, Lyon, 2008, pp285-288
 
2) Oshima K:Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 139:532-544, 2007
 
3) Suzuki R:Leukemia and lymphoma of natural killer cells. J Clin Exp Hematopathol 45:51-70, 2005
 
4) 鈴宮淳司, 大島孝一:NK細胞リンパ腫:病因と臨床像. 臨床血液 49:545-552, 2008
 
5) Suzuki R, Yamamoto K, Seto M, et al.:CD7+and CD56+ myeloid/natural killer cell precursor acute leukemia:a distinct hematolymphoid disease entity. Blood 90:2417-2428, 1997
PubMed
6) Suzuki R, Nakamura S, Suzumiya J, et al.:Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor):prognostication and categorization according to anatomic sites of involvement. Cancer 104:1022-1031, 2005
PubMed
7) Hercend T, Schmidt RE:Characteristics and uses of natural killer cells. Immunol Today 9:291-293, 1988
PubMed
8) Farag SS, Caligiuri MA:Human natural killer cell development and biology. Blood Rev 20:123-137, 2006
PubMed
9) Sanchez MJ, Muench MO, Roncarolo MG, et al.:Identification of a common T/natural killer cell progenitor in human fetal thymus. J Exp Med 180:569-576, 1994
 
10) Ng CS, Chan JK, Lo ST:Expression of natural killer cell markers in non-Hodgkin's lymphomas. Hum Pathol 18:1257-1262, 1987
PubMed
11) 大野敏之, 塚田哲也, 川上惠基ほか:Natural killer 細胞由来の鼻腔原発悪性リンパ腫の1例. 臨床血液 31:487-491, 1990
 
12) Suzumiya J, Takeshita M, Kimura N, et al.:Expression of adult and fetal natural killer cell markers in sinonasal lymphomas. Blood 83:2255-2260, 1994
PubMed
13) Kaneko T, Fukuda J, Yoshihara T, et al.:Nasal natural killer (NK) cell lymphoma:report of a case with activated NK cells containing Epstein-Barr virus and expressing CD21 antigen, and comparative studies of their phenotype and cytotoxicity with normal NK cells. Br J Haematol 91:355-361, 1995
PubMed
14) Kawa-Ha K, Ishihara S, Ninomiya T, et al.:CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest 84:51-55, 1989
PubMed
15) Harabuchi Y, Yamanaka N, Kataura A, et al.:Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 335:128-130, 1990
PubMed
16) Jaffe ES, Chan JK, Su IJ, et al.:Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg J Pathol 20:103-111, 1996
 
17) The World Health Organization classification of malignant lymphomas in Japan:incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 50:696-702, 2000
 
18) Ko YH, Kim CW Park CS, et al.:REAL classification of malignant lymphomas in the Republic of Korea:incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 83:806-812, 1998
 
19) Au WY, Weisenburger DD, Intragumtornchai T, et al.:Clinical differences between nasal and extranasal natural killer/T-cell lymphoma:a study of 136 cases from the International Peripheral T-cell Lymphoma Project. Blood 113:3931-3937, 2009
PubMed
20) Vose J, Armitage J, Weisenburger D, et al.:International peripheral T-cell and naturall killer/T-cell lymphoma study:pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008
 
21) Kwong YL, Chan AC, Liang RH:Natural killer cell lymphoma/leukemia:pathology and treatment. Hematol Oncol 15:71-79, 1997
PubMed
22) Wong KE Chan JK, Cheung MM, et al.:Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. Ann J Clin Pathol 115:266-270, 2001
 
23) Ohshima K, Haraokaa S, Ishihara S, et al.:Analysis of chromosome 6q deletion in EBV-associated NK cell leukaemia/lymphoma. Leuk Lymphoma 43:293-300, 2002
PubMed
24) Nakashima Y, Tagawa H, Suzuki R, et al.:Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia:different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/Tcell lymphoma, nasal type. Genes Chromosomes Cancer 44:247-255, 2005
 
25) Suzumiya J, Ohshima K, Takeshita M, et al.:Nasal lymphomas in Japan:a high prevalence of Epstein-Barr virus type A and deletion within the latent membrane protein gene. Leuk Lymphoma 35:567-578, 1999
PubMed
26) Liu Q, Ohshima K, Sumie A, et al.:Nasal CD56 positive small round cell tumors. Differential diagnosis of hematological, neurogenic, and myogenic neoplasms. Virchows Arch 438:271-279, 2001
PubMed
27) Kako S, Izutsu K, Ota Y, et al.:FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 18:1685-1690, 2007
 
28) Tsukamoto N, Kojima M, Hasegawa M, et al.:The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-pet with 67gallium scintigraphy in the evaluation of lymphoma:relation to histologic subtypes based on the World Health Organization classification. Cancer 110:652-659, 2007
 
29) Miller TP, Dahlberg S, Cassady JR, et al.:Chemotherapy alone compared with chemotherapy plus radiotherapy for localize d intermediate-and high-grade non-Hodgkin's lymphoma. N Engl Med 339:21-26, 1998
 
30) Yamaguchi M, Ogawa S, Nomoto Y, et al.:Treatment outcome of nasal NK-cell lymphoma:A report of 12 consecutively-diagnosed cases and a review of the literature. J Clin Exp Hematopathol 41:93-99, 2001
 
31) Yamaguchi M, Kita K, Miwa H, et al.:Frequent expression of P-glycoprotein/MDRI by nasal T-cell lymphoma cells. Cancer 76:2351-2356, 1995
 
32) Egashira M, Kawamata N, Sugimoto K, et al.:P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 93:599-606, 1999
PubMed
33) Isobe K, Uno T, Tamaru J, et al.:Extranodal natural killer/T-cell lymphoma, nasal type:the significance of radiotherapeutic parameters. Cancer 106:609-615, 2006
PubMed
34) Ribrag V, Ell Hajj M, Janot F, et al.:Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 15:1123-1126, 2001
PubMed
35) Li YX, Yao B, Jin J, et al.:Radiotherapy as primary treatment for stage I E and II E nasal natural killer/T-cell lymphoma. J Clin Oncol 24:181-189, 2006